



OPEN

Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018

Natalia V. Bhattacharjee¹, Lauren E. Schaeffer^{2,3}, Simon I. Hay^{1,4}✉ and Local Burden of Disease Exclusive Breastfeeding Collaborators*

Exclusive breastfeeding (EBF)—giving infants only breast-milk for the first 6 months of life—is a component of optimal breastfeeding practices effective in preventing child morbidity and mortality. EBF practices are known to vary by population and comparable subnational estimates of prevalence and progress across low- and middle-income countries (LMICs) are required for planning policy and interventions. Here we present a geospatial analysis of EBF prevalence estimates from 2000 to 2018 across 94 LMICs mapped to policy-relevant administrative units (for example, districts), quantify subnational inequalities and their changes over time, and estimate probabilities of meeting the World Health Organization’s Global Nutrition Target (WHO GNT) of $\geq 70\%$ EBF prevalence by 2030. While six LMICs are projected to meet the WHO GNT of $\geq 70\%$ EBF prevalence at a national scale, only three are predicted to meet the target in all their district-level units by 2030.

Exclusive breastfeeding (EBF)—giving infants only breast-milk (and medications, vitamins or oral rehydration solution (ORS) as needed) for the first 6 months of life—is effective in preventing deaths from diarrhoea, pneumonia and other leading causes of child mortality^{1–4}. Breast-milk has been characterized as a ‘personalized medicine’ for infants² due to its nutritional properties, natural growth stimulators and tailored immune-protective properties, which collectively contribute to infant growth, development and survival^{5–8}. Furthermore, evidence suggests long-term health benefits of breastfeeding, including reduced risks of cardiovascular diseases and increased benefits to human capital in adulthood^{2,9,10}. The introduction of supplementary food and water during the first 6 months of life, particularly in settings lacking reliable access to clean water, can expose infants to infections from a range of pathogens¹³. Along with the initiation of breastfeeding within the first hour after birth and continued breastfeeding to 2 years, the World Health Organization (WHO) considers EBF to be an optimal breastfeeding practice¹¹ and included it as a proven protective intervention in the Global Action Plan for Pneumonia and Diarrhoea (GAPPD)¹. Despite the benefits, the proportion of exclusively breastfed children remains low in many low- and middle-income countries (LMICs), where most child deaths attributed to suboptimal breastfeeding occur¹². Accelerated uptake in EBF is required to successfully achieve the World Health Organization’s Global Nutrition Target (WHO GNT) of at least 50% EBF prevalence by 2025¹¹ and the recently updated WHO GNT of at least 70% EBF prevalence by 2030¹³.

This study is a part of a body of work mapping high-spatial-resolution estimates to track progress toward the WHO GNTs^{14–17}. Building on our previous geospatial analysis of EBF prevalence in sub-Saharan Africa¹⁴, we synthesized data from 349 geo-referenced household surveys from years 1998 to 2018 representing 302,435 infants under 6 months to produce annual 2000–2018 subnational estimates for the proportion and absolute number of exclusively breastfed infants for 94 LMICs. We used 14 geographically distinct modelling regions which were determined on the

basis of epidemiological homogeneity and geographical contiguity by the Global Burden of Disease (GBD) study¹⁸ (Supplementary Table 4 and Supplementary Fig. 7). We first mapped estimates on a 5 × 5-km grid to align with the resolution of many of the covariates used in this study and then aggregated to more policy-relevant second- and first-administrative-level units for each country in our analysis. Here we provide mapped annual estimates of EBF prevalence and trends at policy-relevant administrative and national levels from 2000 to 2018, as well as the estimated number of infants not receiving EBF. On the basis of trends in the most recent years, we project these estimates to the years 2025 and 2030, and determine the probability of meeting the WHO GNTs of $\geq 50\%$ and $\geq 70\%$ EBF prevalence in the respective target years. Furthermore, we examine relative and absolute subnational inequalities of EBF prevalence within LMICs and compare areas with low EBF prevalence to areas with high disease burden and low coverage of mitigating interventions. The full array of our model outputs—at various spatial levels and aggregations—is available through an online visualization tool (<https://vizhub.healthdata.org/lbd/ebf>), with additional results in the Supplementary Information.

Results

Regional, national and subnational trends in EBF prevalence. EBF prevalence varied widely between and within LMICs from 2000 to 2018 (Fig. 1a,b). General increases in mean EBF prevalence occurred across LMICs over the study period, from 28.6% (95% uncertainty interval: 22.9–35.4%) in 2000 to 38.7% (28.3–49.9%) in 2018. Regionally, most LMICs in Andean South America, South Asia and East Asia had relatively high EBF levels throughout the study period; for example, Peru (63.6% (60.9–66.4%) in 2000; 69.2% (57.6–79.1%) in 2018), Nepal (64.2% (49.1–76.9%) in 2000; 64.5% (53.6–74.3%) in 2018) and Mongolia (51.9% (49.3–54.4%) in 2000; 55.1% (52.1–58.1%) in 2018) all maintained high national EBF prevalence. Several countries in other regions maintained low EBF prevalence throughout the study, including the Dominican Republic (13.2% (9.7–17.8%) in 2000; 8.2% (4.7–14.3%) in 2018),

¹Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, USA. ²Medical Teams International, Seattle, WA, USA. ³Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA, USA. ⁴Department of Nursing, Adigrat University, Adigrat, Ethiopia. *A list of authors and their affiliations appears at the end of the paper. ✉e-mail: sihay@uw.edu

Suriname (6.4% (4.3–9.2%); 5.7% (3.2–9.6%)), Tunisia (10.9% (6.7–17.0%); 12.2% (7.7–18.0%)), Yemen (11.7% (4.7–22.3%); 12.5% (7.3–20.2%)) and Thailand (7.5% (4.9–11.1%); 13.9% (9.8–19.0%)). National 2018 EBF levels varied broadly between countries in the regions of Central America and the Caribbean (8.2% (4.7–14.3%) in the Dominican Republic; 50.7% (40.3–61.7%) in Guatemala), Tropical South America (5.7% (3.2–9.6%) in Suriname; 32.4% (29.1–35.8%) in Paraguay), Central Asia (18.7% (13.9–24.7%) in Uzbekistan; 51.8% (44.9–58.8%) in Afghanistan), Southeast Asia (13.9% (9.8–19.0%) in Thailand; 62.0% (50.4–72.9%) in Cambodia), North Africa (12.2% (7.7–18.0%) in Tunisia; 51.3% (44.7–57.6%) in Sudan) and throughout sub-Saharan Africa. Overall, in 2018, national EBF prevalence varied by as much as 39.2 times across all LMICs, ranging from 2.2% (1.1–4.0%) in Chad (Western sub-Saharan Africa) to 87.7% (76.9–94.2%) in Rwanda (Eastern sub-Saharan Africa).

Select LMICs made notable progress in the study period. In 2000, 57 LMICs had <30% estimated mean EBF prevalence in at least half of their first-administrative-level units (henceforth ‘provinces’); by 2018, eight of these countries had increased mean EBF prevalence to come close to the original WHO GNT of 50% EBF prevalence, with at least 45% EBF in most provinces: Cambodia (88.2%; 30 of 34 provinces), Democratic Republic of the Congo (DRC; 69.2%; 18 of 26), Guinea-Bissau (77.8%; 7 of 9), Lesotho (100.0%; 10 of 10), Liberia (80.0%; 12 of 15), Sudan (88.9%; 16 of 18) and Turkmenistan (66.7%; 4 of 6). For example, Kâmpóng Chhnang province in central Cambodia (19.5% (14.0–26.3%) in 2000; 63.4% (47.5–77.8%) in 2018) and West Kurdufan state in southern Sudan (13.4% (10.4–17.2%) in 2000; 51.9% (40.6–63.0%) in 2018) both experienced large gains. Overall, 34 LMICs had at least one province that made similar gains from <30% to \geq 45% EBF prevalence (45.1%; 296 of 656 provinces across these 34 LMICs).

To compare trends and prevalence levels, we overlaid the highest and lowest population-weighted deciles of EBF at the second-administrative level (henceforth ‘district’) to the highest and lowest deciles of annualized rates of change (AROC) (Fig. 1c). Along with having some of the lowest levels of EBF practice in 2000 and 2018, Chad, Suriname, Somalia and Brazil also had among the highest rates of annualized decline in EBF during the study period. Districts in Niger, Nigeria, Gabon, Yemen, Tunisia, the Dominican Republic, southern Thailand and central Philippines also had among the lowest EBF prevalence levels in both 2000 and 2018; even despite some of the highest rates of EBF increase in southern Vietnam and northeastern Thailand, EBF remained among the lowest levels in these districts in both years (Fig. 1c). Districts throughout much of Peru, southeastern Bolivia, eastern Brazil, Ethiopia, Uganda, Rwanda, Burundi, India, Nepal, Mongolia and the Philippines had among the highest prevalence levels in both years; as did select districts in Guatemala, Zambia, Malawi, Eritrea, Afghanistan, Pakistan and Indonesia. Districts scattered throughout Guatemala, the DRC, northern Liberia, northern Ghana, Eritrea, western Tanzania, Zambia, Malawi, Lesotho, Bangladesh and Cambodia had among the highest levels for the year 2018, as did select districts in western Honduras, eastern and western Sudan and northern Laos. Districts with some of the highest rates of annualized increase in EBF were located in southern Sierra Leone, central Côte d’Ivoire, southern Burkina Faso, central Niger, central Nigeria, Sudan, eastern Ethiopia, DRC, Angola, Namibia, South Africa, northern Mozambique, central Kenya, Turkmenistan, western Kyrgyzstan, Myanmar, northern Thailand, southern Laos and southern Vietnam. In contrast, the highest rates of annualized decline in EBF were seen in eastern Honduras, Colombia, Brazil, eastern Bolivia, eastern Zambia, eastern Ghana, eastern Niger, central Nigeria, central Mozambique, central Madagascar, central Afghanistan and Pakistan. The Philippines and Brazil both had among the best-performing and worst-performing

districts for both years in regard to prevalence and Niger, Nigeria and Mozambique had districts among the highest and lowest rates of annualized change.

By mapping AROC from 2000 to 2018, we show where and to what degree EBF practices have increased or decreased on average over the study period (Fig. 1d). Most district-level units across LMICs experienced increases in estimated mean prevalence of EBF over the study period (62.6%; 15,379 of 24,556 districts), while over a third experienced decreases 37.2% (9,137 of 24,556 districts). Overall, 28 LMICs experienced annualized increases in mean EBF prevalence in all districts; 25 LMICs had >2.5% annualized increase in all districts, including Bangladesh, Cambodia, Botswana, Liberia and Lesotho (Supplementary Table 8a). Sudan, Zimbabwe, South Africa, Kenya, Myanmar and Turkmenistan were among 14 LMICs that experienced among the highest annualized EBF increases (>5% AROC) in all of their districts’ mean estimates (Supplementary Table 8a). In 13 LMICs, most districts had decreasing annualized trends in EBF practice (<0% AROC); Chad was the only LMIC that experienced EBF declines in all of its districts (Supplementary Table 8b). A large proportion (69.1%; 65 of 94) of LMICs had both annualized increases and decreases in EBF across their districts; 7 (7.4%) LMICs had districts that had experienced both extremes of the mapped annualized increases (>5%) and decreases (\leq -2.5%); Nigeria, Somalia, Mozambique, Niger, Thailand, the Philippines and India (Supplementary Table 8c).

Comparison of units with low EBF and other health conditions.

To identify some of the highest-need provinces across LMICs, we compared the lowest decile of EBF prevalence in this study to the highest decile levels of our previously published geospatial estimates of stunting¹⁶, childhood diarrhoea¹⁹ and under-5-yr mortality²⁰ and the lowest decile of coverage of ORS²¹ and access to piped water²² (Supplementary Information section 5.5 and Supplementary Figs. 19–23). Several provinces in Chad had among the lowest levels of EBF, as well as some of the highest levels of under-5-yr mortality, stunting and diarrhoea and some of the lowest coverage levels of ORS and access to piped water. Also among the lowest levels of EBF, select provinces in Nigeria had among the lowest ORS coverage and both Niger and Nigeria had provinces with low EBF prevalence and some of the highest child stunting and mortality rates. Yemen had provinces with codistribution of low EBF prevalence and high levels of child diarrhoea and stunting. Somalia had several provinces with low EBF and high under-5-yr mortality rates, while Gabon had one province with among the highest childhood diarrhoea rates and lowest EBF prevalence. One province in Comoros and several provinces in Thailand had among the lowest levels of EBF as well as access to piped water (Supplementary Table 12).

Geographic inequalities in EBF prevalence. We calculated Gini coefficients as a measure of geographic inequality at the country level²³. Our results suggest that geographic inequality in EBF prevalence decreased in most of the countries from 2000 to 2018 (77 of 94) on the basis of Gini coefficients; while there were 11 countries in 2000 whose Gini coefficient was >0.25, only Nigeria and the Philippines had coefficients above 0.25 in 2018.

We quantified absolute geographic inequalities in EBF prevalence by calculating the absolute differences between district-level units with the lowest and highest prevalence in each country (method details in Supplementary Information section 4.4.3). Between 2000 and 2018, absolute geographic inequalities had increased in over a third (38.3%; 36 of 94) of LMICs, at least doubling in eight countries, including Afghanistan, Jamaica, Jordan, Nepal, Niger, Republic of the Congo, Sierra Leone and Turkmenistan (Fig. 2). Of the 92.6% (88 of 94) of LMICs which had increased in EBF national prevalence, almost half (42.1% (37 of 88)) had also increased in absolute inequalities—including in Afghanistan and Republic of the




Fig. 1 | EBF prevalence and progress (2000–2018) among infants under 6 months across LMICs. a,b, Prevalence of EBF practices at the district level in 2000 (**a**) and 2018 (**b**). **c**, Overlapping population-weighted highest and lowest deciles of prevalence and weighted AROC between 2000 and 2018, at the district level. **d**, Weighted annualized percentage change in EBF prevalence between 2000 and 2018. Maps reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1×1-km grid cell and were classified as 'barren or sparsely vegetated' or were not included in this analysis^{50–55}.

Congo—indicating areas left behind in overall national progress. While 39.3% (37 of 94) of LMICs had increased absolute inequalities between districts, 12.6% (12 of 94) of LMICs decreased their

absolute inequalities; absolute inequalities in the other 45 LMICs in the analysis remained relatively the same. Several countries had reduced absolute inequalities by at least one-third while also




Fig. 2 | Geographic inequalities in EBF prevalence across 94 countries for 2000 and 2018. a, Absolute inequalities: range of EBF estimates in district-level units within 94 LMICs. **b**, Relative inequalities: range of ratios of EBF estimates in district-level units relative to country means. Each dot represents a district-level unit. The lower bound of each bar represents the district-level unit with the lowest EBF in each country. The upper end of each bar represents the district-level unit with the highest EBF in each country. Thus, each bar represents the extent of geographic inequality in EBF estimated for each country. Bars indicating the range in 2018 are coloured according to their GBD super-region. Grey bars indicate the range in EBF in 2000. The black diamond in each bar represents the median EBF estimated across district-level units in each country and year. A coloured bar that is shorter than its grey counterpart indicates that geographic inequality has narrowed. Countries are labeled by their ISO 3 codes (full country names are listed in Supplementary Table 4).

increasing their EBF prevalence, including Burundi, Cuba, Eritrea, Gabon, Guinea, Malawi, Mali, Rwanda, Trinidad and Tobago and Uganda. Absolute inequalities in EBF were at least halved in eight LMICs: Burundi, Chad, Cuba, Eritrea, Gambia, Guinea, Mali and Rwanda. Along with substantial reductions in absolute inequalities, Gambia also substantially increased its national EBF prevalence, while Guinea, Mali and Rwanda experienced marginal increases in national prevalence; Chad, however, had decreased EBF prevalence across all its district-level units. In 2018, absolute differences in EBF between the highest- and lowest-prevalent districts within countries ranged from 1.1 to 45.3 times; São Tomé and Príncipe had the least variation, ranging from 66.0% (29.8–90.9%) in Me-Zochi (São Tomé) to 67.8% (31.3–93.0%) in Pague (Príncipe), while the Philippines ranged from 1.5% (0.9–2.3%) in San Jose (Antique) to 92.8% (88.6–95.9%) in Bagamanoc (Catanduanes). Most LMICs (60.0% (57 of 94)) had twofold or more difference in EBF between districts in 2000; 36.8% (35 of 94) had this difference in 2018. A threefold or greater difference between units was experienced in 34 (35.8%) and 15 (15.8%) LMICs in 2000 and 2018, respectively. A six-fold or greater difference was experienced by 14 (14.7%) LMICs in 2000 and 4 (4.2%) LMICs in 2018—Brazil, Nigeria, the Philippines and Thailand.

We quantified relative inequalities by calculating the relative differences between each district-level unit and its country's average for 2000 and 2018 (Supplementary Information section 4.4.3). Overall, within-country relative inequalities in EBF

coverage declined; 48 LMICs in 2000 and 25 LMICs in 2018 had district-level units that deviated by >50% from the country mean (Fig. 2). Throughout the study period, Belize, Egypt, Eritrea and Papua New Guinea demonstrated low within-country relative differences in EBF, whereas Myanmar, Cambodia, Laos, Ghana and Peru had reduced relative geographic inequalities over time (Fig. 3). As an example, northern districts of Myanmar positively deviated and southwestern districts negatively deviated by $\geq 30\%$ from the national mean in 2000 but these within-country relative differences decreased to <10% from the national mean in either direction by 2018. Within-country relative inequalities remained high, however, in Comoros, Brazil, the Philippines and Guyana in both 2000 and 2018. In 2018, the largest relative inequalities were in Nigeria, Brazil, Thailand and the Philippines. In particular, Nigeria's most negatively deviating district-level units were concentrated in the north and southeast, while central districts loomed largely above the mean in 2018 (20.1% (18.8–21.4%) national mean; 3.4% (1.7–5.9%) in Baure (Osun); 53.7% (41.3–62.7%) in Ife Central (Osun)). Additionally, in Brazil, deviating patterns were scattered, with districts throughout much of the Amazon Basin in the west positively deviating from the national mean (for example, 80.1% (80.8–83.7) in Machadinho municipality (Rondônia) in 2018) and many districts in the Brazilian Highlands negatively deviating from the mean (for example, 10.7% (9.9–11.7%) in Abadia de Goiás municipality (Goiás); national mean 27.1% (25.6–28.6%)).




Fig. 3 | Relative geographic inequalities within countries in EBF prevalence in 2000 and 2018: comparing district-level units to the country-level means. a, b, Relative deviation of EBF prevalence in district-level units from the country-level EBF mean in 2000 (a) and 2018 (b). Blue indicates a positive deviation from the EBF country-level mean, indicating a higher EBF prevalence level. Red indicates a negative deviation from the EBF country-level mean, indicating a lower EBF prevalence level. Maps reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1×1-km grid cell and were classified as ‘barren or sparsely vegetated’ or were not included in this analysis^{50–55}.

Absolute number of children not exclusively breastfed. In 2000, of the ~56,039,700 (51,145,700–60,940,400) infants under 6 months in the populations across the 94 countries in our analysis (according to the 2019 GBD Study²⁴), an estimated 33,489,000 (31,867,900–35,031,200) infants were not exclusively breastfed. In 2018, among a population of ~57,787,200 (51,016,200–64,661,000) infants under 6 months in 94 LMICs²⁴, an estimated 31,878,600 (28,721,500–34,999,000) children were not exclusively breastfed, representing a 4.8% (0.1–9.9%) decrease since 2000. A comparison of shifts in prevalence and numbers of non-EBF children over the past two decades suggests that, despite some of the largest increases in EBF prevalence in Asia and Oceania, the bulk of the total number of infants not benefiting from EBF still comes from these regions (Fig. 4).

Four countries have more than an estimated million infants each that were not exclusively breastfed in 2018 (Fig. 5), accounting for 39.9% of the total: India (5,351,900 (4,825,700–5,904,700); 19.1% of the total non-EBF infants), Nigeria (2,899,100 (2,850,500–2,945,200); 10.4%), Pakistan (1,770,300 (1,653,400–1,889,400); 6.3%) and Brazil (1,157,000 (1,116,400–1,200,800); 4.1%). Eight additional countries each had an estimated half-million children or more that were not exclusively breastfed in 2018, accounting for 17.4% of the total non-EBF infants: Indonesia (982,200 (897,700–1,063,100); 3.5% of the total), the Philippines (782,100 (658,100–893,800); 2.8%), Mexico (760,500 (699,500–813,800); 2.7%), DRC (741,200 (623,700–848,700); 2.7%), Ethiopia (626,800 (427,600–851,000); 2.2%), Bangladesh (609,900 (402,100–832,000); 2.1%), Egypt (574,100 (480,700–670,500); 2.0%) and Vietnam (515,500 (455,800–564,800); 1.8%). Although some of these countries were close to achieving the original WHO GNT of 50%

prevalence by 2018, with >45% mean national prevalence, Mexico has had low EBF prevalence scattered throughout its units and the Philippines has consistently had some of the largest subnational inequalities. Nigeria, Brazil and Vietnam have the dual complications of high geographic inequalities and relatively low national EBF prevalence (<30%).

Projected EBF prevalence in 2025 and 2030. On the basis of previous spatiotemporal historical trends and the assumption that recent trends will continue, we projected EBF estimates for the year 2025 (Supplementary Fig. 17a,b) and 2030 (Fig. 6a,b). Overall, EBF prevalence across LMICs is expected to increase from 38.7% (28.3–49.9%) in 2018 to 42.6% (25.6–60.5%) in 2025 and to reach 45.2% (23.9–67.2%) by 2030. National EBF prevalence is expected to vary by as much as 56.6 times across all LMICs (1.6% (0.5–3.8%) in Chad; 87.9% (67.4–97.0%) in Rwanda) in 2025, while within-country differences are expected to range from 1.1 to 62.9 times, with the most variation in the Philippines, Brazil and Nigeria (ninefold or more difference). By 2030, national-level prevalence is projected to vary by 71.3 times across LMICs (1.2 (0.3–3.7%) in Chad; 87.7% (59.9–98.1%) in Rwanda), with subnational variation ranging from 1.1 to 80.4 times; Brazil, the Philippines and Nigeria are expected to maintain a ninefold or greater difference between districts.

Our predictions for 2025 and 2030 show similar levels of EBF and patterns of subnational inequalities throughout LMICs as in 2018, with a few notable exceptions. On the basis of current trajectories, some of the largest projected gains are expected throughout sub-Saharan Africa. In Guinea-Bissau, Mauritania, Sierra Leone, Namibia, Zimbabwe and Gambia, most districts had <50% mean prevalence in 2018, but these countries are estimated to




Fig. 4 | Number of infants under 6 months who are not being exclusively breastfed, distributed across non-EBF prevalence in 2000 and 2018, across 94 countries. a, Non-EBF infants under 6 months in 2000. **b**, Non-EBF infants under 6 months in 2018. The dotted line in the 2000 plot is the shape of the distribution in 2018 and the dotted line in the 2018 plot represents the distribution in 2000. Bar heights represent the total number of infants under 6 months who were not exclusively breastfed by district-level units, with corresponding non-EBF prevalence. Bins are a width of one non-EBF infant per 100 infants. The colour of each bar represents the global region as defined by the subset legend map. As such, the sum of heights of all bars represents the total number of non-EBF infants across the 94 countries.

meet or exceed the original 50% EBF target in most districts in 2025. Outside of sub-Saharan Africa, Turkmenistan, Myanmar, Indonesia and Kyrgyzstan are also expected to exceed the 50% EBF mean prevalence target in most of their districts by 2025. Projected declines are expected to lead to districts in 15 LMICs that had mean estimates of EBF of $\geq 50\%$ in 2018 to drop below this threshold by 2025; for example, Argo (Badakshan) in northeastern Afghanistan is expected to decrease from 52.4% (32.6–71.9%) in 2018 to 48.9% (17.8–60.45%) in 2025. By 2025, 33 LMICs are projected to have national mean EBF prevalence that meet the original WHO GNT of $\geq 50\%$, while 16 LMICs are predicted to have mean EBF prevalence meeting this target in all of their province-level units; 11 LMICs are expected to meet this target in all of their district-level units by 2025.

By 2030, six LMICs (Burundi, Cambodia, Lesotho, Peru, Rwanda and Sierra Leone) are projected to have mean national EBF prevalence that meet the updated WHO GNT of $\geq 70\%$, while three LMICs (Burundi, Lesotho and Rwanda) are predicted to meet this target in all their province-level and district-level units. Five LMICs (the Philippines, India, Peru, Ghana and Bolivia) had districts that met the $\geq 70\%$ WHO GNT in 2018 which are expected to fall below this threshold in 2030, such as in Sandia (Puno), Peru (70.6% (51.2–88.4%) in 2018; 64.0% (33.8–87.1%) in 2030) and Mallig (Isabella), the Philippines (70.5% (54.5–83.2%) in 2018; 69.1% (38.2–90.0%) in 2030).

Progress towards the 2030 WHO GNT of $\geq 70\%$ EBF. We mapped the probabilities of meeting the updated WHO GNT of $\geq 70\%$ EBF by 2018 and 2030 at various scales (Supplementary Fig. 18 and Fig. 6c).

Across LMICs, 86.2% (81 of 94), 63.8% (60 of 94) and 52.1% (49 of 94) had a low probability ($<5\%$) of having achieved the updated WHO GNT of $\geq 70\%$ EBF at the national level, in all provinces, or in all districts, respectively, by 2018 (Supplementary Table 10a). Rwanda was the only LMIC that had a high probability ($>95\%$) of having already achieved the 70% target in 2018 at the national level, as well as the only LMIC to have had a high probability of meeting the target in all province-level units. No LMIC, however, had a high probability of meeting WHO GNT of 70% in all their district-level units in 2018. Across LMICs, 84.4% (20,717 of 24,556) of districts located in 88 LMICs had a low probability, while only 1.0% (256 of 24,556) of districts in five LMICs had a high probability of having achieved the updated target of 70% by 2018. Three LMICs had districts with both high and low probability of having met the new 70% target by 2018: Brazil, Peru and the Philippines.

In analysing probabilities of meeting the updated WHO GNT of $\geq 70\%$ EBF by the year 2030, most LMICs (56.4% (53 of 94)) are expected to have a low probability ($<5\%$) of nationally achieving this goal; 23.4% (22 of 94) and 13.8% (13 of 94) of LMICs have a low probability of meeting this goal in all of their province- and district-level units, respectively (Supplementary Table 10b). No LMIC has a high probability ($>95\%$) of meeting the $\geq 70\%$ target by 2030 at the national level or in all their province- or district-level units. Across LMICs, only 0.7% (177 of 24,556) of districts located in seven LMICs have a high probability, while 59.1% (14,518 of 24,556) of districts in 56 LMICs have a low probability of meeting the $\geq 70\%$ target by 2030. Extreme subnational inequalities in probabilities (both $<5\%$ and $>95\%$ probability) of achieving the 70%




Fig. 5 | Number of infants under 6 months who are not being exclusively breastfed at the district level, 2000 and 2018. a, b, Number of infants under 6 months who are not being exclusively breastfed, aggregated to district-level units in 2000 (a) and 2018 (b). **c**, Difference in number of infants under 6 months who are not being exclusively breastfed between 2018 and 2000, aggregated to district-level units. Maps reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1×1-km grid cell and were classified as ‘barren or sparsely vegetated’ or were not included in this analysis^{50–55}.

EBF target by 2030 are expected to occur in 3.2% (3 of 94) of LMICs: Brazil, the Philippines and Mongolia. See Supplementary Table 9 and Supplementary Fig. 17 for probabilities of meeting the original WHO GNT of $\geq 50\%$ by 2025.

Discussion

EBF practice has been known to vary by region, country and population^{25–27} but an understanding of the subnational distribution of this heterogeneity is hampered by several limitations in the

previously available estimates. Previous studies have estimated EBF prevalence and interest groups such as UNICEF²⁶ and Countdown to 2030²⁷ have compiled EBF datasets and country profiles; some of these results have been stratified by urban–rural status or wealth quintiles or mapped at the first-administrative level (for example, states, provinces). These maps and datasets, however, are limited to select countries or years and do not allow for comparisons across countries for each year or within countries at more detailed geographic scales. Understanding subnational variation in EBF is




Fig. 6 | Projected prevalence for EBF for 2030 and probability of meeting the $\geq 70\%$ WHO GNT by 2030. a,b, Projected EBF prevalence for 2030 at the national (a) and district (b) levels. c, Probability of meeting the WHO GNT of at least 70% EBF prevalence by 2030 at the district level. Dark blue indicates a high probability ($>95\%$ posterior probability) and dark red indicates a low probability ($<5\%$ posterior probability) of meeting the WHO GNT by 2030. Maps reflect administrative boundaries, land cover, lakes and population; grey-coloured grid cells had fewer than ten people per 1×1 -km grid cell and were classified as 'barren or sparsely vegetated' or were not included in this analysis^{50–55}.

critical to determining where increased breastfeeding support efforts are needed to lead to the most improvement. This study maps comparable subnational estimates of EBF prevalence across most LMICs over an almost 20-yr period, projects these estimates to WHO GNT target years and quantifies within-country inequalities. Not only can these estimates aid tracking progress toward WHO GNTs but also toward the United Nation's Sustainable Development Goal (SDG)²⁸ to reduce national inequalities in health opportunities and outcomes, both between and within countries, by 2030.

Although EBF is considered a cost-effective intervention, it is not free; it requires investment of time and energy from mothers and support from wider networks, including their families, communities, workplaces, health systems and government leadership. Manipulative marketing of breast-milk substitutes^{29,30}, inadequate workplace support³¹, late or lack of attendance at antenatal care³², lack of skilled lactation support or breastfeeding counselling in health facilities^{11,32} and societal beliefs favouring mixed feeding^{11,32–34} all contribute to low rates of EBF^{25,26,35}. The WHO-UNICEF Global

Breastfeeding Collective (GBC) initiative stresses the need for advocacy at global, national and subnational levels to improve breastfeeding rates for the betterment of maternal and child health and wellbeing³⁶. The GBC's Breastfeeding Advocacy Toolkit outlines seven key policy actions to increase breastfeeding practices, which are: increasing funding to support EBF and continued breastfeeding to 2 years; fully adopting and monitoring the International Code of Marketing of Breast-Milk Substitutes ('the Code'); enacting workplace breastfeeding policies and paid family leave; implementing the 'baby-friendly' hospital's 'ten steps to successful breastfeeding'; improving access to skilled breastfeeding counselling in health facilities; strengthening links between health facilities and communities to support breastfeeding; and strengthening monitoring systems to track progress³⁶. Inconsistent implementation of these policies could contribute to the between- and within-country variation we see in EBF practice across LMICs. Combined with information on breastfeeding interventions, our mapped estimates can aid policy-makers in monitoring the success of breastfeeding policy and programme investments.

The World Bank estimates that an investment of US\$4.70 per live newborn is needed to meet the WHO GNT for EBF by 2025^{37,38}. According to the Global Breastfeeding Scorecard, however, only five LMICs in this analysis meet or exceed estimated funding needs (Guinea-Bissau, Haiti, Nepal, Somalia and Timor-Leste), while 50 spend <US\$1 per live birth on breastfeeding support programmes, as of 2018³⁹. Aggressive marketing of breast-milk substitutes (BMS) disrupts mothers' informed choices by providing misleading information. In response to controversial marketing strategies, the World Health Assembly established the Code in 1981 to regulate the promotion and safety of BMS and ensure the adequate nutrition of infants⁴⁰. The Code bans point-of-sale promotion of BMS or bottles, distribution of free samples and misleading promotional materials suggesting a product's superiority over mother's natural milk⁴⁰. In 2018, however, only 24 of the 94 LMICs in this study had comprehensive Code legislation in place and 25 had no legal measures protecting consumers from aggressive BMS marketing tactics³⁹. A study on global infant formulas sales showed that the steepest market increases were in Asia Pacific (18% increase) and Middle East and Africa (14% increase) regions within just 1 year (2012–2013)⁴⁰; by 2025, the infant formula industry is expected to surpass US\$98 billion in sales⁴¹, and increase in marketing and sales will likely negatively affect breastfeeding^{42,43}. Additionally, few LMICs have national policies that satisfy the International Labour Organization's Convention minimum recommendations for 14 weeks of paid maternity leave and appropriate workplace nursing areas; Colombia, Cuba, India, Paraguay, Tajikistan and Vietnam are the only six LMICs in our analysis that fully met these recommendations in 2018³⁹. Individual breastfeeding counselling was reported to be implemented in all primary healthcare facilities in just 28 LMICs³⁹. Of the LMICs with available data, at least half of births were in baby-friendly hospitals and maternities in only six countries (Costa Rica, Cuba, Eswatini, Tajikistan, Thailand and Turkmenistan)³⁹. By subnational reporting, 29 LMICs in the analysis had implemented community programmes in all districts in 2018³⁹. Our estimates, combined with the WHO's Breastfeeding Scorecard Data, can be used to decide where additional resources to support breastfeeding are most needed (Supplementary Information section 5.4).

Positive exemplars in EBF uptake due to policy implementation and financial investments could provide lessons learned for policy-makers to apply towards their countries. The 2018 Global Nutrition Report spotlighted Burkina Faso's strong commitment to supporting breastfeeding through the rapid roll-out of a national infant and young feeding programme that led to all primary healthcare facilities providing counselling and 70% of districts with community programmes for breastfeeding support³⁵. Furthermore, Burkina Faso passed legislation providing 14 weeks of state-funded

maternity leave and laws prohibiting advertising breast-milk substitutes³⁵; by our estimates, most districts experienced >5% annualized increase in EBF over the modelled study period. In Nepal, USAID's integrated nutrition programme combined water and sanitation, family planning and agricultural activities along with essential nutrition and breastfeeding counselling to children and caregivers in 42 of 77 districts and the recommended minimum US\$4.70 per live-birth investment was met in 2018³⁵; by our estimates, all districts in Nepal had annualized EBF increases between 2000 and 2018. The USAID's programming in Malawi worked with the Ministry of Health to achieve 'baby-friendly' status in hospitals, develop a nutrition training for nurses and midwives and provide deworming and vitamin A supplementation³⁵; these combined efforts may have contributed to many of Malawi's districts being >50% of mean EBF prevalence in 2018. Turkmenistan's success in achieving >5% annualized increase in all of its districts by 2018 may be attributed to the high proportion of births in baby-friendly hospitals (86.9%) and community breastfeeding programmes implemented in all its districts³⁹. Gambia and Côte d'Ivoire, which had reduced absolute inequalities by at least a third, fared well on the Breastfeeding Scorecard; basic maternity provisions, as well as community programmes in all districts and counselling in all facilities were reported for Côte d'Ivoire and Gambia had full legal status of the Code, met recommended maternity leave length and all facilities offered counselling. Although we identified Cambodia as having among the highest EBF prevalence levels in 2018, and Myanmar as having among the highest annualized increases, and both countries experienced large reductions in relative inequalities, they did not have widespread supportive breastfeeding policies implemented, according to their 2018 national scorecard³⁹. Additional local investigations are needed to document subnational policy implementation and determine associations between breastfeeding policies and interventions and EBF progress.

This study provides a comprehensive picture of the unmet need for EBF by mapping both prevalence of EBF and the absolute number of children not exclusively breastfed for their first 6 months of life. Our mapped estimates provide a tool to visualize subnational inequalities otherwise masked by national-level estimates and areas left behind in EBF uptake. These subnational EBF estimates can aid policy- and decision-makers in tracking progress towards the international target and in identifying where additional breastfeeding support efforts are needed to improve child health and survival. Comparisons against additional health indicators could inform the development of more comprehensive approaches to improve health in populations most in need. Future research could compare these estimates with breastfeeding policies and interventions, or lack thereof, to determine which were most successful in achieving increased practice of EBF and what barriers still need to be addressed.

Methods

Overview. For this study, we used a similar methodology to that of our previous work on mapping EBF prevalence in Africa⁴⁴ and extended our scope to include all LMICs with available relevant data. LMIC status was determined by sociodemographic index (SDI), which indicates a country's level of development on the basis of poverty, education and fertility as defined in the GBD study. Here we map estimates of countries that have low, low-middle or middle SDI status (Supplementary Table 4). We excluded several countries from our analysis despite low, low-middle or middle status due to lack of relevant input data (Cape Verde, Dominica, Djibouti, Ecuador, Grenada, Iran, Libya, Malaysia, Seychelles, Sri Lanka and Venezuela). This study complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER; <http://gather-statement.org>; Supplementary Information section 1.0).

Data. Surveys and EBF indicator data. When searching the Global Health Data Exchange (GHDx; <http://ghdx.healthdata.org>) for the keyword 'breastfeeding', we compiled an extensive geo-located dataset that includes 345 household surveys (including the Demographic and Health Surveys (DHS), Multiple Indicator Cluster Surveys (MICS) and other country-specific or multinational surveys)

conducted in years 1998 to 2018 in LMICs. Of these, we assigned data from 21 surveys conducted in years 1998 or 1999 to the year 2000 to address data scarcity. This dataset represents 302,435 infants aged 0–5 months (infants up to the age of 6 months) across 94 LMICs and was geocoded to 69,179 coordinates corresponding to cluster-level boundaries and 67,750 subnational polygon boundaries. Across the 94 countries in the analysis, there were 1,727 first-administrative-level boundaries (for example, provinces) and 24,556 second-administrative-level boundaries (for example, districts). Overall inclusion criteria for surveys included: conducted in an LMIC between 1998 and 2018; responses available at the individual level; contains subnational geographic identifiers (that is, GPS coordinates, cluster or administrative units) with survey weights for each observation; and contains questions and responses about child's age and breastfeeding status. A survey was included if it contained questions and responses regarding whether the child had consumed other food or liquids besides breast-milk. We only included observations of children who were under 6 months at the time of the survey (0–5 months). See the Supplementary Information sections 2.1 and 2.2 for further details on exclusion and inclusion criteria.

Spatial covariates. In these analyses, we included 11 socioeconomic and health-related covariates identified as conceivably associated with breastfeeding practices: (1) travel time to the nearest settlement >50,000 inhabitants, (2) nighttime lights^{TV}, (3) population^{TV}, (4) number of children under 5 yr per woman of childbearing age^{TV}, (5) urban proportion of the location^{TV}, (6) number of people whose daily vitamin A needs could be met, (7) educational attainment in women of reproductive age (15–49-years-old)^{TV}, (8) human development index (HDI)^{TV}, (9) human immunodeficiency virus (HIV) prevalence^{TV}, (10) healthcare access and quality index^{TV} and (11) proportion of pregnant women who received four or more antenatal care visits^{TV} (where superscript TV indicates time-varying covariates). Of these, the covariates for the Healthcare Access and Quality Index⁴⁴ and the proportion of pregnant women who received four or more antenatal care visits⁴⁵ were indexed at the national level, while all others were indexed at the subnational level. The spatial covariates were selected because they are factors or proxies for factors that previous literature has identified to be associated (not necessarily causally) with EBF prevalence.

Variance inflation factor⁴⁶ (VIF) analysis was used to filter covariates for multicollinearity. We performed temporal processing for covariates that did not have information for every year of the modelled study period and filled in intervening years with the value from the nearest neighbouring year or used an exponential growth rate model. Detailed information on covariates can be found in Supplementary Table 5 and Supplementary Fig. 8.

Analysis. The technical descriptions of methods for the underlying geostatistical model, model validation and postestimation are consistent with those previously used in the geospatial modelling of EBF across Africa¹⁴.

Geostatistical model. EBF was modelled using a Bayesian geostatistical approach. This approach uses a hierarchical logistic regression model that is spatially and temporally explicit, and assumes points close in space and time and with similar covariate patterns will have similar levels of EBF. Using a stacked generalization technique, we also incorporated potential nonlinear relationships between covariates and EBF input data. For all model parameters and hyper-parameters, we used the R-INLA statistical package to approximate posterior distributions⁴⁷. We used 1,000 draws from these approximate joint posterior distributions to calculate uncertainty intervals (UI), determining and reporting the 2.5th and 97.5th percentiles of those 1,000 draws. Further details on methodology can be found in Supplementary Information section 4.0. Extended Data Fig. 1 provides an overview of analytical processing steps involved in the analysis.

Model validation. We used fivefold cross validation to validate models, as summarized below. Complete methods used for validation and related results are available in the Supplementary Information. First, we combined randomized sets of cluster-level data points at the first-administrative level to create holdout sets. Afterwards, we fit the geostatistical model five times, sequentially excluding each of the five groups of data, and provided out-of-sample predictions that correspond to all included surveys in the analysis. We summarized the performance of the model using 95% data coverage within prediction intervals, correlation between predictions and observed data and the mean error (a measure of bias) and root-mean-square error (a measure of total variance). Model estimates were also compared with other existing estimates, as possible.

Postestimation. To estimate EBF prevalence at various levels (province, district and country), we aggregated each of the 1,000 draws of coverage at the 5 × 5-km grid-cell level, weighted by population. We performed posthoc calibration of our estimates to the GBD 2019 estimates¹². This allowed us to include data sources outside of the scope of our geospatial modelling framework. On the basis of the estimates, we calculated absolute differences between lowest and highest administrative units and relative differences between a country's average and each administrative unit in that country to quantify geographic inequality. We performed a simple projection calculation by comparing the estimated rates of

EBF improvement between 2000 and 2018 with the improvements needed between 2018 and 2030 to meet the WHO GNT (Supplementary Information section 4.4.4). The national time series and aggregated input data in our estimates can be found in Extended Data Fig. 2.

Modelling limitations. The modelling limitations in this work are consistent with those previously described in the geospatial modelling of EBF across Africa¹⁴.

While we have attempted to propagate uncertainty from various sources through the different modelling stages, there are some sources of uncertainty that have not been propagated. In particular, it was not computationally feasible to propagate uncertainty from the submodels in stacking through the geostatistical model. Similarly, although the WorldPop population raster is also composed of estimates associated with some uncertainty, this uncertainty is difficult to quantify and not currently reported and we were unable to propagate this uncertainty into our estimates of EBF prevalence for administrative units that were created using population-weighted averages of grid-cell estimates. Model fitting was carried out using an integrated nested Laplace approximation to the posterior distribution, as implemented in the R-INLA package⁴⁷. Prediction from fitted models was subsequently carried out using the `inla.posterior.sample()` function, which generates samples from the approximated posterior of the fitted model. Both model fitting and prediction thus require approximations, and these approximations may introduce error.

To estimate projections of EBF prevalence levels in 2025 and 2030, we used previous historical trends and the assumption that recent trends will continue. These assumptions in turn lend to modelling limitations, as we were not able to project underlying drivers of changes in EBF, such as increasing urbanization or changes in population^{35,48,49}, and the certainty of our estimates and projections were critically dependent on data quality and availability. Availability of relevant data varies both spatially and temporally across LMICs (Supplementary Figs. 1–5) and lack of relevant data is one of the main sources of uncertainty around our estimates (as seen in Extended Data Fig. 3). We have mapped EBF prevalence levels against the relative uncertainty of our estimates in Extended Data Fig. 3.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The information given here is mostly consistent with our previous study modelling EBF across Africa¹⁴. The findings of this study are supported by data that are available in public online repositories, data that are publicly available on request from the data provider and data that are not publicly available due to restrictions by the data provider and which were used under license for the current study. Details on data sources can be found on the GHDx website (http://ghdx.healthdata.org/lbd-publication-data-input-source?s?field_rec_ihme_publication_tid=29093), including information about the data provider and links to where the data can be accessed or requested (where available). We have also provided maps of the data included in our models in Supplementary Figs. 1–5. Outputs of these EBF analyses can be explored at various spatial levels (national, administrative and 5 × 5-km levels) through our customized visualization tool (<https://vizhub.healthdata.org/lbd/ebf>) and are publicly available at the GHDx (<http://ghdx.healthdata.org/record/ihme-data/global-exclusive-breastfeeding-prevalence-geospatial-estimates-2000-2019>). Administrative boundaries were retrieved from the Database of Global Administrative Areas (GADM)⁵⁰. Land cover was retrieved from the online Data Pool, courtesy of the NASA EOSDIS Land Processes Distributed Active Archive Center, USGS/Earth Resources Observation and Science Center, Sioux Falls, South Dakota⁵¹. Lakes were retrieved from the Global Lakes and Wetlands Database, courtesy of the World Wildlife Fund and the Center for Environmental Systems Research, University of Kassel⁵². Populations were retrieved from WorldPop⁵³. All maps in this study were produced using ArcGIS Desktop 10.6.

Code availability

All codes used for these analyses are publicly available online at <https://github.com/ihmeuw/lbd/tree/ebf-lmic-2021>.

Received: 22 May 2020; Accepted: 31 March 2021;
Published online: 3 June 2021

References

- Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025: The Integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD) (WHO & UNICEF, 2013); https://www.who.int/maternal_child_adolescent/documents/global_action_plan_pneumonia_diarrhoea/en/
- Victoria, C. G. et al. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet* **387**, 475–490 (2016).
- Bhutta, Z. A. et al. Interventions to address deaths from childhood pneumonia and diarrhoea equitably: what works and at what cost? *Lancet* **381**, 1417–1429 (2013).

4. Darmstadt, G. et al. Evidence-based, cost-effective interventions: how many newborn babies can we save? *Lancet* **11**, 977–988 (2005).
5. O'Sullivan, A., Farver, M. & Smilowitz, J. T. The influence of early infant-feeding practices on the intestinal microbiome and body composition in infants. *Nutr. Metab. Insights* **8**, 1–9 (2015).
6. Ballard, O. & Morrow, A. L. Human milk composition: nutrients and bioactive factors. *Pediatr. Clin. N. Am.* **60**, 49–74 (2013).
7. Kramer, M. S. & Kakuma, R. Optimal duration of exclusive breastfeeding. *Cochrane Database Syst. Rev.* **554**, 63–77 (2012).
8. *From the First Hour of Life: Making The Case for Improved Infant and Young Child Feeding Everywhere* (UNICEF, 2016); https://www.unicef.org/publications/index_93027.html
9. Horta, B. L., Loret de Mola, C. & Victora, C. G. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-analysis. *Acta Paediatr.* **104**, 30–37 (2015).
10. Horta, B. L. et al. *Evidence on the Long-term Effects of Breastfeeding* (WHO, 2007).
11. *Global Nutrition Targets 2025—Breastfeeding Policy Brief* (WHO & UNICEF, 2014); http://www.who.int/nutrition/publications/globaltargets2025_policybrief_breastfeeding/en/
12. Murray, C. J. L. et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1223–1249 (2020).
13. *The Extension of the 2025 Maternal, Infant and Young Child Nutrition Targets to 2030* (WHO & UNICEF, 2018); <https://www.who.int/nutrition/global-target-2025/discussion-paper-extension-targets-2030.pdf?ua=1>
14. Bhattacharjee, N. V. et al. Mapping exclusive breastfeeding in Africa between 2000 and 2017. *Nat. Med.* **25**, 1205–1212 (2019).
15. Osgood-Zimmerman, A. et al. Mapping child growth failure in Africa between 2000 and 2015. *Nature* **555**, 41–47 (2018).
16. Kinyoki, D. K. et al. Mapping child growth failure across low- and middle-income countries. *Nature* **577**, 231–234 (2020).
17. Kinyoki, D. K. et al. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. *Nat. Med.* **26**, 750–759 (2020).
18. Murray, C. J. et al. GBD 2010: design, definitions, and metrics. *Lancet* **380**, 2063–2066 (2012).
19. Reiner, R. C. Jr. et al. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. *Lancet* **395**, 1779–1801 (2020).
20. Burstein, R. et al. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. *Nature* **574**, 353–358 (2019).
21. Wiens, K. E. et al. Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. *Lancet Glob. Health* **8**, e1038–e1060 (2020).
22. Deshpande, A. et al. Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. *Lancet Glob. Health* **8**, e1162–e1185 (2020).
23. De Maio, F. G. Income inequality measures. *J. Epidemiol. Community Health* **61**, 849–852 (2007).
24. Wang, H. et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* **396**, 1160–1203 (2020).
25. Roberts, T. J., Carnahan, E. & Gakidou, E. Can breastfeeding promote child health equity? A comprehensive analysis of breastfeeding patterns across the developing world and what we can learn from them. *BMC Med.* **11**, 254 (2013).
26. *Infant and Young Child Feeding* (UNICEF, 2019); <https://data.unicef.org/topic/nutrition/infant-and-young-child-feeding/>
27. *The Countdown Country Profile: A Tool for Action* (Countdown to 2030, accessed 10 February 2020); <http://countdown2030.org/country-and-regional-networks/country-profiles>
28. *Sustainable Development Goals* (UN, accessed 10 February 2020); <https://www.un.org/sustainabledevelopment/sustainable-development-goals/>
29. *Marketing of Breast-milk Substitutes: National Implementation of the International Code, Status Report 2018* (WHO, UNICEF & IBFAN, 2018).
30. Piwoz, E. G. & Huffman, S. L. The impact of marketing of breast-milk substitutes on WHO-recommended breastfeeding practices. *Food Nutr. Bull.* **36**, 373–386 (2015).
31. Chai, Y., Nandi, A. & Heymann, J. Does extending the duration of legislated paid maternity leave improve breastfeeding practices? Evidence from 38 low-income and middle-income countries. *BMJ. Glob. Health* **3**, e001032 (2018).
32. Kavle, J., LaCroix, E., Dau, H. & Engmann, C. Addressing barriers to exclusive breast-feeding in low- and middle-income countries: a systematic review and programmatic implications. *Public Health Nutr.* **20**, 3120–3134 (2017).
33. Quinn, V. J. et al. Improving breastfeeding practices on a broad scale at the community level: success stories from Africa and Latin America. *J. Hum. Lact.* **21**, 345–354 (2005).
34. *A Successful Start in Life: Improving Breastfeeding in West and Central Africa* (UNICEF, 2010); https://www.unicef.org/health/files/wcaro_improving_breastfeeding_en.pdf
35. *2018 Global Nutrition Report* (Global Nutrition Report, 2018); <https://globalnutritionreport.org/reports/global-nutrition-report-2018/>
36. Global Breastfeeding Collective. *Breastfeeding Advocacy Toolkit*. Knowledge for Health (K4Health) (Johns Hopkins Center for Communication Programs, 2 August 2019); <https://www.k4health.org/toolkits/breastfeeding-advocacy-toolkit>
37. Walters, D., Eberwein, J. D., Sullivan, L., D'Alimonte, M. & Shekar, M. *An Investment Framework for Meeting the Global Nutrition Target for Breastfeeding* (World Bank Group, 2017).
38. *Increasing Commitment to Breastfeeding Through Funding and Improved Policies and Programmes: Global Breastfeeding Scorecard 2019* (WHO & UNICEF, 2019); <http://www.who.int/nutrition/publications/infantfeeding/global-bf-scorecard-2019/en/>
39. Global Breastfeeding Collective. *Scorecard Data* (Tableau Software, 2018); <https://public.tableau.com/profile/gbc2364#!/vizhome/Tables2/Dashboard1?publish=yes>
40. *International Code of Marketing of Breast-milk Substitutes* (WHO, 1981); <https://www.who.int/nutrition/publications/infantfeeding/9241541601/en/>
41. *Infant Formula Market Value to Hit \$98 billion by 2025: Global Market Insights, Inc.* (Global Market Insights, 2019); <http://www.globenewswire.com/news-release/2019/04/17/1805213/0/en/Infant-formula-Market-value-to-hit-98-billion-by-2025-Global-Market-Insights-Inc.html>
42. Rollins, N. C. et al. Why invest, and what it will take to improve breastfeeding practices? *Lancet* **387**, 491–504 (2016).
43. Sinha, B. et al. Interventions to improve breastfeeding outcomes: a systematic review and meta-analysis. *Acta Paediatr.* **104**, 114–134 (2015).
44. Fullman, N. et al. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet* **391**, 2236–2271 (2018).
45. Lozano, R. et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* **392**, 2091–2138 (2018).
46. Faraway, J. J. *Linear Models with R* Ch. 4 (CRC Press, 2004).
47. Rue, H., Martino, S. & Chopin, N. Approximate Bayesian inference for latent Gaussian models by using integrated nested Laplace approximations (with discussion). *J. R. Stat. Soc. B* **71**, 319–392 (2009).
48. Lugina, H. I. Breastfeeding commitments and challenges in Africa. *Afr. J. Midwifery Women's Health* <https://doi.org/10.12968/ajmw.2011.5.1.4> (2011).
49. Perez-Escamilla, R. Breastfeeding in Africa and the Latin American and Caribbean Region: the potential role of urbanization. *J. Trop. Pediatr.* **40**, 137–143 (1994).
50. *GADM Database of Global Administrative Areas* (GADM, 2018); <http://www.gadm.org>
51. Terra and Aqua Combined MODIS Version 5.1 (Land Processes Distributed Active Archive Center, accessed 24 July 2019).
52. *Global Lakes and Wetlands Database, Level 3* (WWF, 2004); <https://www.worldwildlife.org/pages/global-lakes-and-wetlands-database>
53. *WorldPop Datasets* (WorldPop, accessed 22 January 2019); http://www.worldpop.org.uk/data/get_data/
54. Tatem, A. J. WorldPop, open data for spatial demography. *Sci. Data* **4**, 170004 (2017).
55. Lehner, B. & Döll, P. Development and validation of a global database of lakes, reservoirs and wetlands. *J. Hydrol.* **296**, 1–22 (2004).

Acknowledgements

This work was primarily supported by grant no. OPP1132415 from the Bill & Melinda Gates Foundation. Co-authors used by the Bill & Melinda Gates Foundation (E.G.P. and R.R.3) provided feedback on initial maps and drafts of this manuscript. L.G.A. has received support from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brasil (CAPES), Código de Financiamento 001 and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (grant nos. 404710/2018-2 and 310797/2019-5). O.O.Adetokunboh acknowledges the National Research Foundation, Department of Science and Innovation and South African Centre for Epidemiological Modelling and Analysis. M.Ausloos, A.Pana and C.H. are partially supported by a grant from the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project no. PN-III-P4-ID-PCCF-2016-0084. P.C.B. would like to acknowledge the support of F. Alam and A. Hussain. T.W.B. was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. K.Deribe is supported by the Wellcome Trust (grant no. 201900/Z/16/Z) as part of his international intermediate fellowship. C.H. and A.Pana are partially supported by a grant of the

Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project no. PN-III-P2-2.1-SOL-2020-2-0351. B.Hwang is partially supported by China Medical University (CMU109-MF-63), Taichung, Taiwan. M.Khan acknowledges Jatiya Kabi Kazi Nazrul Islam University for their support. A.M.K. acknowledges the other collaborators and the corresponding author. Y.K. was supported by the Research Management Centre, Xiamen University Malaysia (grant no. XMUMRF/2020-C6/ITM/0004). K.Krishan is supported by a DST PURSE grant and UGC Centre of Advanced Study (CAS II) awarded to the Department of Anthropology, Panjab University, Chandigarh, India. M.Kumar would like to acknowledge FIC/NIH K43 TW010716-03. L.L. is a member of the Sistema Nacional de Investigación (SNI), which is supported by the Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT), Panamá. M.L. was supported by China Medical University, Taiwan (CMU109-N-22 and CMU109-MF-118). W.M. is currently a programme analyst in Population and Development at the United Nations Population Fund (UNFPA) Country Office in Peru, which does not necessarily endorse this study. D.E.N. acknowledges Cochrane South Africa, South African Medical Research Council. G.C.P. is supported by an NHMRC research fellowship. P.Rathi acknowledges support from Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. Ramu Rawat acknowledges the support of the GBD Secretariat for supporting the reviewing and collaboration of this paper. B.R. acknowledges support from Manipal College of Health Professions, Manipal Academy of Higher Education, Manipal. A.Ribeiro was supported by National Funds through FCT, under the programme of 'Stimulus of Scientific Employment—Individual Support' within the contract no. CEECIND/02386/2018. S.Sajadi acknowledges colleagues at Global Burden of Diseases and Local Burden of Disease. A.M.S. acknowledges the support from the Egyptian Fulbright Mission Program. F.S. was supported by the Shenzhen Science and Technology Program (grant no. KQTD20190929172835662). A.Sheikh is supported by Health Data Research UK. B.K.S. acknowledges Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal for all the academic support. B.U. acknowledges support from Manipal Academy of Higher Education, Manipal. C.S.W. is supported by the South African Medical Research Council. Y.Z. was supported by Science and Technology Research Project of Hubei Provincial Department of Education (grant no. Q20201104) and Outstanding Young and Middle-aged Technology Innovation Team Project of Hubei Provincial Department of Education (grant no. T2020003). The funders of the study had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. All maps presented in this study are generated by the authors and no permissions are required to publish them.

Author contributions

S.I.H. and L.D.-L. conceived and planned the study. D.L., S.J.S., J.Albright, W.M.G., B.V.P., C.L., K.M.D., E.G.P., Rahul Rawat and B.Sartorius identified and obtained data for analysis. D.L., S.J.S., J.Albright, W.M.G., N.J.H., C.L., A.L.-A., B.V.P. and K.M.D. extracted, processed and geospatialized the data. N.V.B. carried out the statistical analyses to produce estimates. A.E.O.-Z., N.J.H., M.L.C., M.A.C., D.K.K., J.F.M., A.Deshpande, L.W., J.D.V., K.E.W., R.C.R. and L.D.-L. provided input on the methods. N.V.B., D.L., K.B.J., I.D.L. and K.M.D. prepared the figures and tables. L.E.S., N.Davis

Weaver and L.B.M. managed the publications processes and N.V.B., M.F.S., L.D.-L., N.J.K. and S.I.H. managed the estimation processes. M.F.S. served as project manager for the study. N.V.B. and L.E.S. wrote the first draft of the manuscript and all authors contributed to subsequent revisions. All authors provided intellectual input into aspects of this study; additional author contributions can be found in the Supplementary Information.

Competing interests

R.A. reports he received consultancy or speakers fees from UCB, Sandoz, Abbvie, Zentiva, Teva, Laropharm, CEGEDIM, Angelini, Biessen Pharma, Hofigal, AstraZeneca and Stada. A.Deshpande reports grants from Bill & Melinda Gates Foundation, during the conduct of the study. J.J.J. reports personal fees from Boehringer Ingelheim, Zentiva, Amgen and Teva, all outside the submitted work. K.Krishan reports grants from DST PURSE and UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. J.F.M. reports grants from Bill & Melinda Gates Foundation during the conduct of the study. S.R.P. reports non-financial support from Somnogen Canada Inc. and personal fees from editorial services, during the conduct of the study. E.U. reports having a Patent A system and method of reusable filters for anti-pollution mask pending and a Patent A system and method for electricity generation through crop stubble by using microbial fuel cells pending. All other authors declare no competing interests.

Additional information

Extended data is available for this paper at <https://doi.org/10.1038/s41562-021-01108-6>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41562-021-01108-6>.

Correspondence and requests for materials should be addressed to S.I.H.

Peer review information *Nature Human Behaviour* thanks Ranadip Chowdhury, Paulo Augusto Neves and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons

Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

Local Burden of Disease Exclusive Breastfeeding Collaborators

Natalia V. Bhattacharjee¹, Lauren E. Schaeffer^{2,3}, Dan Lu¹, Megan F. Schipp¹, Alice Lazzar-Atwood¹, Katie M. Donkers¹, Gdiom Gebreheat Abady⁴, Foad Abd-Allah⁵, Ahmed Abdelalim⁵, Zeleke Hailemariam Abebo⁶, Ayenew Negesse Abejie⁷, Akine Eshete Abosetugn⁸, Lucas Guimarães Abreu⁹, Michael R. M. Abrigo¹⁰, Eman Abu-Gharbieh¹¹, Abdelrahman I. Abushouk^{12,13}, Aishatu L. Adamu^{14,15}, Isaac Akinkunmi Adedeji¹⁶, Adeyinka Emmanuel Adegbosin¹⁷, Victor Adekanmbi¹⁸, Olatunji O. Adetokunboh^{19,20}, Marcela Agudelo-Botero²¹, Budi Aji²², Oluwaseun Oladapo Akinyemi^{23,24}, Alehegn Aderaw Alamneh²⁵, Fahad Mashhour Alanezi²⁶, Turki M. Alanzi²⁷, James Albright¹, Jacqueline Elizabeth Alcalde-Rabanal²⁸, Biresaw Wassihun Alemu^{29,30}, Robert Kaba Alhassan³¹, Beriwani Abdulqadir Ali^{32,33}, Saqib Ali³⁴, Cyrus Alinia³⁵, Vahid Alipour^{36,37}, Arianna Maeve L. Amit^{38,39}, Dickson A. Amugsi⁴⁰, Etsay Woldu Anbesu⁴¹, Robert Ancuceanu⁴², Mina Anjomshoa⁴³, Fereshteh Ansari^{44,45}, Carl Abelardo T. Antonio^{46,47}, Davood Anvari^{48,49}, Jalal Arabloo³⁶, Amit Arora^{50,51}, Kurnia Dwi Artanti⁵², Mulusew A. Asemahagn⁵³, Wondwossen Niguse Asmare⁵⁴, Maha Moh'd Wahbi Atout⁵⁵, Marcel Ausloos^{56,57}, Nefsu Awoke⁵⁸, Beatriz Paulina Ayala Quintanilla⁵⁹,

Martin Amogre Ayanore⁶⁰, Yared Asmare Aynalem⁶¹, Muluken Altaye Ayza⁶²,
 Zelalem Nigussie Azene⁶³, B. B. Darshan⁶⁴, Ashish D. Badiye⁶⁵, Atif Amin Baig⁶⁶,
 Shankar M. Bakkannavar⁶⁷, Maciej Banach^{68,69}, Palash Chandra Banik⁷⁰,
 Till Winfried Bärnighausen^{71,72}, Huda Basaleem⁷³, Mohsen Bayati⁷⁴, Bayisa Abdissa Baye⁷⁵,
 Neeraj Bedi^{76,77}, Sefealem Assefa Belay⁷⁸, Akshaya Srikanth Bhagavathula^{79,80}, Dinesh Bhandari^{81,82},
 Nikha Bhardwaj⁸³, Pankaj Bhardwaj^{84,85}, Zulfiqar A. Bhutta^{86,87}, Ali Bijani⁸⁸, Tsegaye Adane Birhan⁸⁹,
 Binyam Minuye Birihane^{90,91}, Zebeay Workneh Bitew^{92,93}, Somayeh Bohlouli⁹⁴, Mahdi Bohluli^{95,96},
 Hunduma Amensisa Bojia⁹⁷, Archith Bolor⁹⁸, Oliver J. Brady⁹⁹, Nicola Luigi Bragazzi¹⁰⁰,
 Andre R. Brunoni^{101,102}, Shyam S. Budhathoki¹⁰³, Sharath Burugina Nagaraja¹⁰⁴, Zahid A. Butt^{105,106},
 Rosario Cárdenas¹⁰⁷, Joao Mauricio Castaldelli-Maia¹⁰⁸, Franz Castro¹⁰⁹, Achille Cernigliaro¹¹⁰,
 Jaykaran Charan¹¹¹, Pranab Chatterjee¹¹², Souranshu Chatterjee¹¹³, Vijay Kumar Chattu^{114,115},
 Sarika Chaturvedi¹¹⁶, Mohiuddin Ahsanul Kabir Chowdhury^{117,118}, Dinh-Toi Chu¹¹⁹, Michael L. Collison¹,
 Aubrey J. Cook¹, Michael A. Cork¹, Rosa A. S. Couto¹²⁰, Baye Dagne¹²¹, Haijiang Dai^{122,123},
 Lalit Dandona^{1,124,125}, Rakhi Dandona^{1,124,126}, Parnaz Daneshpajouhnejad^{127,128},
 Aso Mohammad Darwesh¹²⁹, Amira Hamed Darwish¹³⁰, Ahmad Daryani¹³¹, Jai K. Das¹³²,
 Rajat Das Gupta^{118,133}, Claudio Alberto Dávila-Cervantes¹³⁴, Adrian Charles Davis^{135,136},
 Nicole Davis Weaver¹, Edgar Denova-Gutiérrez¹³⁷, Kebede Deribe^{138,139}, Assefa Desalew¹⁴⁰,
 Aniruddha Deshpande¹⁴¹, Awrajaw Dessie⁸⁹, Keshab Deuba^{142,143},
 Samath Dhamminda Dharmaratne^{1,126,144}, Meghnath Dhimal¹⁴⁵, Govinda Prasad Dhungana¹⁴⁶,
 Daniel Diaz^{147,148}, Alireza Didarloo¹⁴⁹, Isaac Oluwafemi Dipeolu¹⁵⁰, Linh Phuong Doan¹⁵¹,
 Bereket Duko^{152,153}, Andre Rodrigues Duraes^{154,155}, Laura Dwyer-Lindgren^{1,126}, Lucas Earl¹,
 Maysaa El Sayed Zaki¹⁵⁶, Maha El Tantawi¹⁵⁷, Teshome Bekele Elema^{158,159}, Hala Rashad Elhabashy¹⁶⁰,
 Shaimaa I. El-Jaafary⁵, Pawan Sirwan Faris^{161,162}, Andre Faro¹⁶³, Farshad Farzadfar¹⁶⁴,
 Valery L. Feigin^{1,165,166}, Berhanu Elfu Feleke¹⁶⁷, Tomas Y. Ferede¹⁶⁸, Florian Fischer¹⁶⁹, Nataliya A. Foigt¹⁷⁰,
 Morenike Oluwatoyin Folayan¹⁷¹, Richard Charles Franklin¹⁷², Mohamed M. Gad^{173,174},
 Shilpa Gaidhane¹⁷⁵, William M. Gardner¹, Biniyam Sahiledengle Geberemariam¹⁷⁶,
 Birhan Gebresillassie Gebregiorgis⁶¹, Ketema Bizuwork Gebremedhin¹⁷⁷, Berhe Gebremichael¹⁷⁸,
 Fariborz Ghaffarpasand¹⁷⁹, Syed Amir Gilani^{180,181}, Themba G. Ginindza¹⁸², Mustefa Glagn¹⁸³,
 Mahaveer Golechha¹⁸⁴, Kebebe Bekele Gonfa¹⁸⁵, Bárbara Niegia Garcia Goulart¹⁸⁶, Nachiket Gudi¹⁸⁷,
 Davide Guido¹⁸⁸, Rashid Abdi Guled¹⁸⁹, Yuming Guo^{190,191}, Samer Hamidi¹⁹²,
 Demelash Woldeyohannes Handiso¹⁹³, Ahmed I. Hasaballah¹⁹⁴, Amr Hassan⁵, Khezhar Hayat^{195,196},
 Mohamed I. Hegazy⁵, Behnam Heidari¹⁹⁷, Nathaniel J. Henry¹⁹⁸, Claudiu Herteliu^{57,199},
 Hagos Degefa de Hidru²⁰⁰, Hung Chak Ho²⁰¹, Chi Linh Hoang²⁰², Ramesh Holla⁶⁴, Julia Hon¹,
 Mostafa Hosseini^{203,204}, Mehdi Hosseinzadeh³⁶, Mowafa Househ²⁰⁵, Mohamed Hsairi²⁰⁶,
 Guoqing Hu²⁰⁷, Tanvir M. Huda^{117,208}, Bing-Fang Hwang²⁰⁹, Segun Emmanuel Ibitoye¹⁵⁰,
 Olayinka Stephen Ilesanmi^{210,211}, Irena M. Ilic²¹², Milena D. Ilic²¹³, Leebek Raja Inbaraj²¹⁴,
 Usman Iqbal²¹⁵, Seyed Sina Naghibi Irvani²¹⁶, M. Mofizul Islam²¹⁷, Chidozie C. D. Iwu²¹⁸,
 Chinwe Juliana Iwu^{20,219}, Animesh Jain²²⁰, Manthan Dilipkumar Janodia²²¹, Tahereh Javaheri²²²,
 Yetunde O. John-Akinola¹⁵⁰, Kimberly B. Johnson¹, Farahnaz Joukar^{223,224}, Jacek Jerzy Jozwiak²²⁵,
 Ali Kabir²²⁶, Leila R. Kalankesh²²⁷, Rohollah Kalhor^{228,229}, Ashwin Kamath^{64,230}, Naser Kamyari²³¹,
 Other Tanuj Kanchan²³², Neeti Kapoor⁶⁵, Behzad Karami Matin²³³, Salah Eddin Karimi²³⁴,
 Habtamu Kebebe Kasaye²³⁵, Getinet Kassahun²³⁶, Nicholas J. Kassebaum^{1,126,237},
 Gbenga A. Kayode^{238,239}, Ali Kazemi Karyani²³³, Peter Njenga Keiyoro²⁴⁰, Bayew Kelkay²⁴¹,

Nauman Khalid²⁴², Md. Nuruzzaman Khan²⁴³, Khaled Khatab^{244,245}, Amir M. Khater²⁴⁶, Mona M. Khater²⁴⁷, Mahalaqua Nazli Khatib²⁴⁸, Yun Jin Kim²⁴⁹, Ruth W. Kimokoti²⁵⁰, Damaris K. Kinyoki^{1,126}, Adnan Kisa^{251,252}, Sezer Kisa²⁵³, Soewarta Kosen²⁵⁴, Kewal Krishan²⁵⁵, Vaman Kulkarni²²⁰, G. Anil Kumar¹²⁴, Manasi Kumar^{256,257}, Nithin Kumar²²⁰, Pushendra Kumar²⁵⁸, Om P. Kurmi^{259,260}, Dian Kusuma^{261,262}, Carlo La Vecchia²⁶³, Sheetal D. Lad²⁶⁴, Faris Hasan Lami²⁶⁵, Iván Landires^{266,267}, Van Charles Lansingh^{268,269}, Savita Lasrado²⁷⁰, Paul H. Lee²⁷¹, Kate E. LeGrand¹, Ian D. Letourneau¹, Sonia Lewycka^{272,273}, Bingyu Li²⁷⁴, Ming-Chieh Li²⁷⁵, Shanshan Li²⁷⁶, Xuefeng Liu²⁷⁷, Rakesh Lodha²⁷⁸, Jaifred Christian F. Lopez^{279,280}, Celia Louie¹, Daiane Borges Machado^{281,282}, Venkatesh Maled^{283,284}, Shokofeh Maleki²⁸⁵, Deborah Carvalho Malta²⁸⁶, Abdullah A. Mamun²⁸⁷, Navid Manafi^{288,289}, Mohammad Ali Mansournia²⁰³, Chabila Christopher Mapoma²⁹⁰, Laurie B. Marczak¹, Francisco Rogerlândio Martins-Melo²⁹¹, Man Mohan Mehndiratta^{292,293}, Fabiola Mejia-Rodriguez²⁹⁴, Tefera Chane Mekonnen²⁹⁵, Walter Mendoza²⁹⁶, Ritesh G. Menezes²⁹⁷, Endalkachew Worku Mengesha²⁹⁸, Abera M. Mersha²⁹⁹, Ted R. Miller^{153,300}, G. K. Mini^{301,302}, Erkin M. Mirrakhimov^{303,304}, Sanjeev Misra³⁰⁵, Masoud Moghadaszadeh^{306,307}, Dara K. Mohammad^{308,309}, Abdollah Mohammadian-Hafshejani³¹⁰, Jemal Abdu Mohammed³¹¹, Shafiu Mohammed^{71,312}, Ali H. Mokdad^{1,126}, Pablo A. Montero-Zamora^{313,314}, Masoud Moradi²³³, Rahmatollah Moradzadeh³¹⁵, Paula Moraga³¹⁶, Jonathan F. Mosser¹, Seyyed Meysam Mousavi³¹⁷, Amin Mousavi Khaneghah³¹⁸, Sandra B. Munro¹, Moses K. Muriithi³¹⁹, Ghulam Mustafa^{320,321}, Saravanan Muthupandian³²², Ahamarshan Jayaraman Nagarajan^{323,324}, Gurudatta Naik³²⁵, Mukhammad David Naimzada^{326,327}, Vinay Nangia³²⁸, Bruno Ramos Nascimento^{329,330}, Vinod C. Nayak⁶⁷, Rawlance Ndejjo³³¹, Duduzile Edith Ndwandwe³³², Ionut Negoii^{333,334}, Georges Nguéfac-Tsague³³⁵, Josephine W. Ngunjiri³³⁶, Cuong Tat Nguyen³³⁷, Diep Ngoc Nguyen^{151,338}, Huong Lan Thi Nguyen³³⁷, Samuel Negash Nigussie³³⁹, Tadesse T. N. Nigussie³³⁹, Rajan Nikbakhsh³⁴⁰, Chukwudi A. Nnaji^{219,341}, Virginia Nunez-Samudio^{342,343}, Bogdan Oancea³⁴⁴, Onome Bright Oghenetega³⁴⁵, Andrew T. Olagunju^{346,347}, Bolajoko Olubukunola Olusanya³⁴⁸, Jacob Olusegun Olusanya³⁴⁸, Muktar Omer Omer³⁴⁹, Obinna E. Onwujekwe³⁵⁰, Doris V. Ortega-Altamirano³⁵¹, Aaron E. Osgood-Zimmerman¹, Nikita Otstavnov³²⁶, Stanislav S. Otstavnov^{326,352}, Mayowa O. Owolabi^{353,354}, P. A. Mahesh³⁵⁵, Jagadish Rao Padubidri⁶⁴, Adrian Pana^{57,356}, Anamika Pandey³⁵⁷, Seithikurippu R. Pandi-Perumal³⁵⁸, Helena Ulliyartha Pangaribuan³⁵⁹, Shradha S. Parsekar³⁶⁰, Deepak Kumar Pasupula³⁶¹, Urvish K. Patel³⁶², Ashish Pathak^{363,364}, Mona Pathak³⁶⁵, Sanjay M. Pattanshetty¹⁸⁷, George C. Patton^{366,367}, Kebreab Paulos³⁶⁸, Veincent Christian Filipino Pepito³⁶⁹, Brandon V. Pickering¹, Marina Pinheiro³⁷⁰, Ellen G. Piwoz³⁷¹, Khem Narayan Pokhrel³⁷², Hadi Pourjafar^{373,374}, Sergio I. Prada^{375,376}, Dimas Ria Angga Pribadi³⁷⁷, Zahiruddin Quazi Syed³⁷⁸, Mohammad Rabiee³⁷⁹, Navid Rabiee³⁸⁰, Fakher Rahim^{381,382}, Shadi Rahimzadeh^{383,164}, Azizur Rahman³⁸⁴, Mohammad Hifz Ur Rahman³⁸⁵, Amir Masoud Rahmani^{386,387}, Rajesh Kumar Rai^{388,389}, Chhabi Lal Ranabhat^{390,391}, Sowmya J. Rao³⁹², Prateek Rastogi³⁹³, Priya Rathi⁶⁴, David Laith Rawaf^{394,395}, Salman Rawaf^{396,397}, Reza Rawassizadeh³⁹⁸, Rahul Rawat³⁹⁹, Ramu Rawat⁴⁰⁰, Lemma Demissie Regassa¹⁷⁸, Maria Albertina Santiago Rego⁴⁰¹, Robert C. Reiner Jr^{1,126}, Bhageerathy Reshmi^{402,403}, Aziz Rezapour³⁶, Ana Isabel Ribeiro⁴⁰⁴, Jennifer Rickard^{405,406}, Leonardo Roever⁴⁰⁷, Susan Fred Rumisha^{408,409}, Godfrey M. Rwegerera⁴¹⁰, Rajesh Sagar⁴¹¹, S. Mohammad Sajadi^{412,413}, Marwa Rashad Salem⁴¹⁴, Abdallah M. Samy⁴¹⁵, Milena M. Santric-Milicevic^{212,416}, Sivan Yegnanarayana Iyer Saraswathy^{417,418},

Abdur Razzaque Sarker⁴¹⁹, Benn Sartorius^{126,420,421}, Brijesh Sathian^{422,423}, Deepak Saxena^{378,424}, Alyssa N. Sbarra¹, Debarka Sengupta⁴²⁵, Subramanian Senthilkumaran⁴²⁶, Feng Sha⁴²⁷, Omid Shafaat^{428,429}, Amira A. Shaheen⁴³⁰, Masood Ali Shaikh⁴³¹, Ali S. Shalash⁴³², Mohammed Shannawaz⁴³³, Aziz Sheikh^{434,435}, B. Suresh Kumar Shetty³⁹³, Ranjitha S. Shetty⁴³⁶, Kenji Shibuya⁴³⁷, Wondimeneh Shibabaw Shiferaw⁶¹, Jae Il Shin⁴³⁸, Diego Augusto Santos Silva⁴³⁹, Narinder Pal Singh⁴⁴⁰, Pushpendra Singh⁴⁴¹, Surya Singh⁴⁴², Yitagesu Sintayehu⁴⁴³, Valentin Yurievich Skryabin⁴⁴⁴, Anna Aleksandrovna Skryabina⁴⁴⁵, Amin Soheili⁴⁴⁶, Shahin Soltani²³³, Muluken Bekele Sorrie¹⁸³, Emma Elizabeth Spurlock¹, Krista M. Steuben¹, Agus Sudaryanto⁴⁴⁷, Mu'awiyah Babale Sufiyan⁴⁴⁸, Scott J. Swartz^{449,450}, Eyayou Girma Tadesse⁴⁵¹, Animut Tagele Tamiru²⁴¹, Leili Tapak^{231,452}, Md. Ismail Tareque⁴⁵³, Ingan Ukur Tarigan⁴⁵⁴, Getayeneh Antehunegn Tesema⁴⁵⁵, Fisaha Haile Tesfay^{456,457}, Abinet Teshome⁴⁵¹, Zemenu Tadesse Tessema⁴⁵⁸, Kavumpurathu Raman Thankappan⁴⁵⁹, Rekha Thapar²²⁰, Nihal Thomas⁴⁶⁰, Roman Topor-Madry^{461,462}, Marcos Roberto Tovani-Palone^{463,464}, Eugenio Traini⁴⁶⁵, Bach Xuan Tran⁴⁶⁶, Phuong N. Truong⁴⁶⁷, Berhan Tsegaye B. T. Tsegaye²³⁶, Irfan Ullah⁴⁶⁸, Chukwuma David Umeokonkwo⁴⁶⁹, Bhaskaran Unnikrishnan⁴⁷⁰, Era Upadhyay⁴⁷¹, Benjamin S. Chudi Uzochukwu⁴⁷², John David VanderHeide⁴⁷³, Francesco S. Violante^{474,475}, Bay Vo⁴⁷⁶, Yohannes Dibaba Wado⁴⁷⁷, Yasir Waheed⁴⁷⁸, Richard G. Wamai^{479,480}, Fang Wang⁴⁸¹, Yafeng Wang⁴⁸², Yuan-Pang Wang¹⁰², Nuwan Darshana Wickramasinghe⁴⁸³, Kirsten E. Wiens⁴⁸⁴, Charles Shey Wiysonge^{219,341}, Lauren Woyczynski¹, Ai-Min Wu⁴⁸⁵, Chenkai Wu^{486,487}, Tomohide Yamada⁴⁸⁸, Sanni Yaya^{489,490}, Alex Yeshaneh⁴⁹¹, Yigizie Yeshaw⁴⁵⁸, Yordanos Gizachew Yeshitila²⁹⁹, Mekdes Tigistu Yilma⁴⁹², Paul Yip^{493,494}, Naohiro Yonemoto^{495,496}, Tewodros Yosef³³⁹, Mustafa Z. Younis^{497,498}, Abdilahi Yousuf Yousuf³⁴⁹, Chuanhua Yu⁴⁸², Yong Yu⁴⁹⁹, Deniz Yuce⁵⁰⁰, Shamsa Zafar^{501,502}, Syed Saoud Zaidi⁵⁰³, Leila Zaki⁵⁰⁴, Josefina Zakzuk⁵⁰⁵, Maryam Zamanian³¹⁵, Heather J. Zar^{506,507}, Mikhail Sergeevich Zastrozhin^{508,509}, Anasthasia Zastrozhina⁵¹⁰, Desalege Amare Zelellw⁵¹¹, Yunquan Zhang^{512,513}, Zhi-Jiang Zhang⁵¹⁴, Xiu-Ju George Zhao^{481,515}, Sanjay Zodpey⁵¹⁶, Yves Miel H. Zuniga^{517,518} and Simon I. Hay^{1,126}


⁵Department of Neurology, Cairo University, Cairo, Egypt. ⁶Department of Public Health, Arba Minch University, Arba Minch, Ethiopia. ⁷Debre Markos University, Debre Markos, Ethiopia. ⁸Department of Public Health, Debre Berhan University, Debre Brehan, Ethiopia. ⁹Department of Pediatric Dentistry, Federal University of Minas Gerais, Belo Horizonte, Brazil. ¹⁰Department of Research, Philippine Institute for Development Studies, Quezon City, Philippines. ¹¹Department of Clinical Sciences, University of Sharjah, Sharjah, United Arab Emirates. ¹²Harvard Medical School, Harvard University, Boston, MA, USA. ¹³Department of Medicine, Ain Shams University, Cairo, Egypt. ¹⁴Community Medicine Department, Bayero University Kano, Kano, Nigeria. ¹⁵Infectious Diseases Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. ¹⁶Department of Sociology, Olabisi Onabanjo University, Ago-Iwoye, Nigeria. ¹⁷School of Medicine, Griffith University, Gold coast, QLD, Australia. ¹⁸Population Health Sciences, King's College London, London, England. ¹⁹Centre of Excellence for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa. ²⁰Department of Global Health, Stellenbosch University, Cape Town, South Africa. ²¹Center for Policy, Population & Health Research, National Autonomous University of Mexico, Mexico City, Mexico. ²²Faculty of Medicine and Public Health, Jenderal Soedirman University, Purwokerto, Indonesia. ²³Department of Health Policy and Management, University of Ibadan, Ibadan, Nigeria. ²⁴Department of Health Policy and Management, University College Hospital, Ibadan, Ibadan, Nigeria. ²⁵Department of Human Nutrition and Food Sciences, Debre Markos University, Debre Markos, Ethiopia. ²⁶Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ²⁷Health Information Management and Technology Department, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ²⁸Center for Health System Research, National Institute of Public Health, Cuernavaca, Mexico. ²⁹College of Medicine and Health Science, Arba Minch University, Arba Minch, Ethiopia. ³⁰Department of Midwifery, Arba Minch University, Injbara, Ethiopia. ³¹Institute of Health Research, University of Health and Allied Sciences, Ho, Ghana. ³²Erbil Technical Health College, Erbil Polytechnic University, Erbil, Iraq. ³³School of Pharmacy, Tishk International University, Erbil, Iraq. ³⁴Department of Information Systems, College of Economics and Political Science, Sultan Qaboos University, Muscat, Oman. ³⁵Department of Health Care Management and Economics, Urmia University of Medical Science, Urmia, Iran. ³⁶Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ³⁷Health Economics Department, Iran University of Medical Sciences, Tehran, Iran. ³⁸School of Medicine and Public Health, Ateneo De Manila University, Manila, Philippines. ³⁹College of Medicine, University of the Philippines Manila, Manila, Philippines. ⁴⁰Maternal and Child Wellbeing, African Population and Health Research Center, Nairobi, Kenya. ⁴¹Department of Public Health, Samara University, Samara, Ethiopia. ⁴²Pharmacy Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ⁴³Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. ⁴⁴Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. ⁴⁵Razi Vaccine and Serum Research Institute, Agricultural Research, Education, and Extension Organization (AREEO), Tehran, Iran. ⁴⁶Department of Health Policy and Administration, University of the Philippines Manila, Manila, Philippines. ⁴⁷Department of Applied Social Sciences, Hong Kong Polytechnic University, Hong Kong, China. ⁴⁸Department of Parasitology, Mazandaran University of Medical Sciences,

Sari, Iran. ⁴⁹Department of Parasitology, Iranshahr University of Medical Sciences, Iranshahr, Iran. ⁵⁰School of Health Sciences, Western Sydney University, Campbelltown, NSW, Australia. ⁵¹Discipline of Child and Adolescent Health, University of Sydney, Westmead, NSW, Australia. ⁵²Department of Epidemiology, Airlangga University, Surabaya, Indonesia. ⁵³School of Public Health, Bahir Dar University, Bahir Dar, Ethiopia. ⁵⁴Department of Nursing, Mizan-Tepi University, Mizan Teferi, Ethiopia. ⁵⁵Faculty of Nursing, Philadelphia University, Amman, Jordan. ⁵⁶School of Business, University of Leicester, Leicester, UK. ⁵⁷Department of Statistics and Econometrics, Bucharest University of Economic Studies, Bucharest, Romania. ⁵⁸Department of Nursing, Wolaita Sodo University, Wolaita Sodo, Ethiopia. ⁵⁹The Judith Lumley Centre, La Trobe University, Melbourne, VIC, Australia. ⁶⁰Department of Health Policy Planning and Management, University of Health and Allied Sciences, Ho, Ghana. ⁶¹Department of Nursing, Debre Berhan University, Debre Berhan, Ethiopia. ⁶²Department of Pharmacology and Toxicology, Mekelle University, Mekelle, Ethiopia. ⁶³Department of Reproductive Health, University of Gondar, Gondar, Ethiopia. ⁶⁴Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India. ⁶⁵Department of Forensic Science, Government Institute of Forensic Science, Nagpur, India. ⁶⁶Unit of Biochemistry, Universiti Sultan Zainal Abidin (Sultan Zainal Abidin University), Kuala Terengganu, Malaysia. ⁶⁷Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Manipal, India. ⁶⁸Department of Hypertension, Medical University of Lodz, Lodz, Poland. ⁶⁹Polish Mothers' Memorial Hospital Research Institute, Lodz, Poland. ⁷⁰Department of Non-communicable Diseases, Bangladesh University of Health Sciences, Dhaka, Bangladesh. ⁷¹Heidelberg Institute of Global Health (HIGH), Heidelberg University, Heidelberg, Germany. ⁷²T.H. Chan School of Public Health, Harvard University, Boston, MA, USA. ⁷³School of Public Health and Community Medicine, Aden College, Aden, Yemen. ⁷⁴Health Human Resources Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ⁷⁵Department of Public Health, Ambo University, Ambo, Ethiopia. ⁷⁶Department of Community Medicine, Gandhi Medical College Bhopal, Bhopal, India. ⁷⁷Jazan University, Jazan, Saudi Arabia. ⁷⁸Department of Biomedical Science, Bahir Dar University, Bahir Dar, Ethiopia. ⁷⁹Department of Social and Clinical Pharmacy, Charles University, Hradec Kralova, Czech Republic. ⁸⁰Institute of Public Health, United Arab Emirates University, Al Ain, United Arab Emirates. ⁸¹School of Public Health, University of Adelaide, Adelaide, SA, Australia. ⁸²Public Health Research Laboratory, Tribhuvan University, Kathmandu, Nepal. ⁸³Department of Anatomy, Government Medical College Pali, Pali, India. ⁸⁴Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Jodhpur, India. ⁸⁵School of Public Health, All India Institute of Medical Sciences, Jodhpur, India. ⁸⁶Centre for Global Child Health, University of Toronto, Toronto, ON, Canada. ⁸⁷Centre of Excellence in Women & Child Health, Aga Khan University, Karachi, Pakistan. ⁸⁸Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran. ⁸⁹Department of Environmental and Occupational Health and Safety, University of Gondar, Gondar, Ethiopia. ⁹⁰Ethiopian Public Health Institute, Addis Ababa, Ethiopia. ⁹¹Department of Nursing, Debre Tabor University, Debre Tabor, Ethiopia. ⁹²Nutrition Department, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. ⁹³St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. ⁹⁴Department of Veterinary Medicine, Islamic Azad University, Kermanshah, Iran. ⁹⁵Department of Computer Science and Information Technology, Institute for Advanced Studies in Basic Sciences, Zanjan, Iran. ⁹⁶Department of Research and Innovation, Petanux Research GmbH, Bonn, Germany. ⁹⁷School of Pharmacy, Haramaya University, Harar, Ethiopia. ⁹⁸Department of Internal Medicine, Manipal Academy of Higher Education, Mangalore, India. ⁹⁹Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. ¹⁰⁰University of Genoa, Genoa, Italy. ¹⁰¹Department of Internal Medicine, University of São Paulo, São Paulo, Brazil. ¹⁰²Department of Psychiatry, University of São Paulo, São Paulo, Brazil. ¹⁰³Research Division, Golden Community, Kathmandu, Nepal. ¹⁰⁴Department of Community Medicine, Employee State Insurance Post Graduate Institute of Medical Sciences and Research, Bangalore, India. ¹⁰⁵School of Public Health and Health Systems, University of Waterloo, Waterloo, ON, Canada. ¹⁰⁶Al Shifa School of Public Health, Al Shifa Trust Eye Hospital, Rawalpindi, Pakistan. ¹⁰⁷Department of Health Care, Metropolitan Autonomous University, Mexico City, Mexico. ¹⁰⁸Department of Psychiatry, University of São Paulo, Sao Paulo, Brazil. ¹⁰⁹Gorgas Memorial Institute for Health Studies, Panama City, Panama. ¹¹⁰Regional Epidemiological Observatory Department, Sicilian Regional Health Authority, Palermo, Italy. ¹¹¹Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, India. ¹¹²Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. ¹¹³Department of Microbiology & Infection Control, Medanta Medicity, Gurugram, India. ¹¹⁴Department of Medicine, University of Toronto, Toronto, ON, Canada. ¹¹⁵Global Institute of Public Health (GIPH), Thiruvananthapuram, India. ¹¹⁶Research Department, Dr. D. Y. Patil University, Pune, India. ¹¹⁷Maternal and Child Health Division, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh. ¹¹⁸Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC, USA. ¹¹⁹Center for Biomedicine and Community Health, VNU International School, Hanoi, Vietnam. ¹²⁰Department of Chemical Sciences, University of Porto, Porto, Portugal. ¹²¹Department of Human Physiology, University of Gondar, Gondar, Ethiopia. ¹²²Department of Cardiology, Central South University, Changsha, China. ¹²³Department of Mathematics and Statistics, York University, Toronto, ON, Canada. ¹²⁴Public Health Foundation of India, Gurugram, India. ¹²⁵Indian Council of Medical Research, New Delhi, India. ¹²⁶Department of Health Metrics Sciences, School of Medicine, University of Washington, Seattle, WA, USA. ¹²⁷Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹²⁸Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran. ¹²⁹Department of Information Technology, University of Human Development, Sulaymaniyah, Iraq. ¹³⁰Department of Pediatrics, Tanta University, Tanta, Egypt. ¹³¹Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, Iran. ¹³²Division of Women and Child Health, Aga Khan University, Karachi, Pakistan. ¹³³James P Grant School of Public Health, BRAC University, Dhaka, Bangladesh. ¹³⁴Department of Population and Development, Latin American Faculty of Social Sciences Mexico, Mexico City, Mexico. ¹³⁵Department of Surgery and Cancer, Imperial College London, London, UK. ¹³⁶Ear Institute, University College London, London, UK. ¹³⁷Center for Nutrition and Health Research, National Institute of Public Health, Cuernavaca, Mexico. ¹³⁸Wellcome Trust Brighton and Sussex Centre for Global Health Research, Brighton and Sussex Medical School, Brighton, UK. ¹³⁹School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia. ¹⁴⁰School of Nursing and Midwifery, Haramaya University, Harar, Ethiopia. ¹⁴¹Department of Epidemiology, Emory University, Atlanta, GA, USA. ¹⁴²National Centre for AIDS and STD Control, Save the Children, Kathmandu, Nepal. ¹⁴³Department of Global Public Health, Karolinska Institute, Stockholm, Sweden. ¹⁴⁴Department of Community Medicine, University of Peradeniya, Peradeniya, Sri Lanka. ¹⁴⁵Health Research Section, Nepal Health Research Council, Kathmandu, Nepal. ¹⁴⁶Department of Microbiology, Far Western University, Mahendranagar, Nepal. ¹⁴⁷Center of Complexity Sciences, National Autonomous University of Mexico, Mexico City, Mexico. ¹⁴⁸Faculty of Veterinary Medicine and Zootechnics, Autonomous University of Sinaloa, Culiacán Rosales, Mexico. ¹⁴⁹Department of Public Health, Urmia University of Medical Science, Urmia, Iran. ¹⁵⁰Department of Health Promotion and Education, University of Ibadan, Ibadan, Nigeria. ¹⁵¹Institute for Global Health Innovations, Duy Tan University, Da Nang, Vietnam. ¹⁵²School of Public Health, Hawassa University, Hawassa, Ethiopia. ¹⁵³School of Public Health, Curtin University, Perth, WA, Australia. ¹⁵⁴School of Medicine, Federal University of Bahia, Salvador, Brazil. ¹⁵⁵Department of Internal Medicine, Escola Bahiana de Medicina e Saúde Pública (Bahiana School of Medicine and Public Health), Salvador, Brazil. ¹⁵⁶Clinical Pathology Department, Mansoura Faculty of Medicine, Mansoura, Egypt. ¹⁵⁷Pediatric Dentistry and Dental Public Health Department, Alexandria University, Alexandria, Egypt. ¹⁵⁸Department of Food Science and Nutrition, Arsi University, Asella, Ethiopia. ¹⁵⁹Center for Food Science and Nutrition, Addis Ababa University, Addis Ababa, Ethiopia. ¹⁶⁰Neurophysiology Department, Cairo University, Cairo, Egypt. ¹⁶¹Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy. ¹⁶²Department of Biology, Cihan University-Erbil, Erbil, Iraq. ¹⁶³Department of Psychology, Federal University of Sergipe, São Cristóvão, Brazil. ¹⁶⁴Non-communicable Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran. ¹⁶⁵National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, Auckland, New Zealand. ¹⁶⁶Research Center of Neurology, Moscow, Russia. ¹⁶⁷Department of Epidemiology and Biostatistics, Bahir Dar University, Bahir Dar, Ethiopia. ¹⁶⁸School of Nursing, Hawassa University, Hawassa, Ethiopia. ¹⁶⁹Institute of Gerontological Health Services and Nursing Research, Ravensburg-Weingarten University of Applied Sciences, Weingarten, Germany. ¹⁷⁰Institute of


Gerontology, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine. ¹⁷¹Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife, Nigeria. ¹⁷²School of Public Health, Medical, and Veterinary Sciences, James Cook University, Douglas, QLD, Australia. ¹⁷³Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA. ¹⁷⁴Gillings School of Global Public Health, University of North Carolina Chapel Hill, Chapel Hill, NC, USA. ¹⁷⁵Department of Medicine, Datta Meghe Institute of Medical Science, Wardha, India. ¹⁷⁶Department of Public Health, Madda Walabu University, Bale Robe, Ethiopia. ¹⁷⁷Department of Nursing and Midwifery, Addis Ababa University, Addis Ababa, Ethiopia. ¹⁷⁸School of Public Health, Haramaya University, Harar, Ethiopia. ¹⁷⁹Department of Neurosurgery, Shiraz University of Medical Sciences, Shiraz, Iran. ¹⁸⁰Faculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan. ¹⁸¹Afro-Asian Institute, Lahore, Pakistan. ¹⁸²Discipline of Public Health Medicine, University of KwaZulu-Natal, Durban, South Africa. ¹⁸³Department of Public Health, Arba Minch University, Arba Minch, Ethiopia. ¹⁸⁴Health Systems and Policy Research, Indian Institute of Public Health Gandhinagar, Gandhinagar, India. ¹⁸⁵Department of Surgery, Mada Walabu University, Bale Robe, Ethiopia. ¹⁸⁶Postgraduate Program in Epidemiology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. ¹⁸⁷Department of Health Policy, Manipal Academy of Higher Education, Manipal, India. ¹⁸⁸UO Neurologia, Salute Pubblica e Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta (Neurology, Public Health and Disability Unit, Carlo Besta Neurological Institute), Milan, Italy. ¹⁸⁹College of Medicine and Health Science, Jijiga University, Jijiga, Ethiopia. ¹⁹⁰Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia. ¹⁹¹Department of Epidemiology, Binzhou Medical University, Yantai City, China. ¹⁹²School of Health and Environmental Studies, Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates. ¹⁹³Department of Public Health, Wachemo University, Hossana, Ethiopia. ¹⁹⁴Department of Zoology and Entomology, Al Azhar University, Cairo, Egypt. ¹⁹⁵Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan. ¹⁹⁶Department of Pharmacy Administration and Clinical Pharmacy, Xian Jiaotong University, Xian, China. ¹⁹⁷Endocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran. ¹⁹⁸Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. ¹⁹⁹School of Business, London South Bank University, London, UK. ²⁰⁰Department of Public Health, Adigrat University, Adigrat, Ethiopia. ²⁰¹Department of Urban Planning and Design, University of Hong Kong, Hong Kong, China. ²⁰²Center of Excellence in Behavioral Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam. ²⁰³Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran. ²⁰⁴Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran. ²⁰⁵College of Science and Engineering, Hamad Bin Khalifa University, Doha, Qatar. ²⁰⁶Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia. ²⁰⁷Department of Epidemiology and Health Statistics, Central South University, Changsha, China. ²⁰⁸School of Public Health, University of Sydney, Sydney, NSW, Australia. ²⁰⁹Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan. ²¹⁰Department of Community Medicine, University of Ibadan, Ibadan, Nigeria. ²¹¹Department of Community Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ²¹²Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ²¹³Department of Epidemiology, University of Kragujevac, Kragujevac, Serbia. ²¹⁴Division of Community Health and Family Medicine, Bangalore Baptist Hospital, Bangalore, India. ²¹⁵College of Public Health, Taipei Medical University, Taipei, Taiwan. ²¹⁶Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²¹⁷School of Psychology and Public Health, La Trobe University, Melbourne, VIC, Australia. ²¹⁸School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa. ²¹⁹South African Medical Research Council, Cape Town, South Africa. ²²⁰Department of Community Medicine, Manipal Academy of Higher Education, Mangalore, India. ²²¹Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India. ²²²Health Informatic Lab, Boston University, Boston, MA, USA. ²²³Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran. ²²⁴Caspian Digestive Disease Research Center, Guilan University of Medical Sciences, Rasht, Iran. ²²⁵Department of Family Medicine and Public Health, University of Opole, Opole, Poland. ²²⁶Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Iran. ²²⁷School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran. ²²⁸Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran. ²²⁹Health Services Management Department, Qazvin University of Medical Sciences, Qazvin, Iran. ²³⁰Manipal Academy of Higher Education, Manipal, India. ²³¹Department of Biostatistics, Hamadan University of Medical Sciences, Hamadan, Iran. ²³²Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences, Jodhpur, India. ²³³Research Center for Environmental Determinants of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²³⁴Social Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ²³⁵School of Nursing and Midwifery, Wollega University, Nekemte, Ethiopia. ²³⁶School of Midwifery, Hawassa University, Hawassa, Ethiopia. ²³⁷Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA, USA. ²³⁸International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria. ²³⁹Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands. ²⁴⁰Open, Distance and eLearning Campus, University of Nairobi, Nairobi, Kenya. ²⁴¹Department of Midwifery, University of Gondar, Gondar, Ethiopia. ²⁴²School of Food and Agricultural Sciences, University of Management and Technology, Lahore, Pakistan. ²⁴³Department of Population Science, Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh. ²⁴⁴Faculty of Health and Wellbeing, Sheffield Hallam University, Sheffield, UK. ²⁴⁵College of Arts and Sciences, Ohio University, Zanesville, OH, USA. ²⁴⁶National Hepatology and Tropical Medicine Research Institute, Cairo University, Cairo, Egypt. ²⁴⁷Department of Medical Parasitology, Cairo University, Cairo, Egypt. ²⁴⁸Global Evidence Synthesis Initiative, Datta Meghe Institute of Medical Sciences, Wardha, India. ²⁴⁹School of Traditional Chinese Medicine, Xiamen University Malaysia, Sepang, Malaysia. ²⁵⁰Department of Nutrition, Simmons University, Boston, MA, USA. ²⁵¹School of Health Sciences, Kristiania University College, Oslo, Norway. ²⁵²Global Community Health and Behavioral Sciences, Tulane University, New Orleans, LA, USA. ²⁵³Department of Nursing and Health Promotion, Oslo Metropolitan University, Oslo, Norway. ²⁵⁴Independent Consultant, Jakarta, Indonesia. ²⁵⁵Department of Anthropology, Panjab University, Chandigarh, India. ²⁵⁶Department of Psychiatry, University of Nairobi, Nairobi, Kenya. ²⁵⁷Division of Psychology and Language Sciences, University College London, London, UK. ²⁵⁸International Institute for Population Sciences, Mumbai, India. ²⁵⁹Faculty of Health and Life Sciences, Coventry University, Coventry, UK. ²⁶⁰Department of Medicine, McMaster University, Hamilton, ON, Canada. ²⁶¹Imperial College Business School, Imperial College London, London, UK. ²⁶²Faculty of Public Health, University of Indonesia, Depok, Indonesia. ²⁶³Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. ²⁶⁴Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India. ²⁶⁵Department of Community and Family Medicine, University of Baghdad, Baghdad, Iraq. ²⁶⁶Unit of Genetics and Public Health, Institute of Medical Sciences, Las Tablas, Panama. ²⁶⁷Ministry of Health, Herrera, Panama. ²⁶⁸HelpMeSee, New York, NY, USA. ²⁶⁹Mexican Institute of Ophthalmology, Queretaro, Mexico. ²⁷⁰Department of Otorhinolaryngology, Father Muller Medical College, Mangalore, India. ²⁷¹School of Nursing, Hong Kong Polytechnic University, Hong Kong, China. ²⁷²Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. ²⁷³Oxford University Clinical Research Unit, Wellcome Trust Asia Programme, Hanoi, Vietnam. ²⁷⁴Department of Sociology, Shenzhen University, Shenzhen, China. ²⁷⁵Department of Public Health, China Medical University, Taichung, Taiwan. ²⁷⁶School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. ²⁷⁷Department of Systems, Populations, and Leadership, University of Michigan, Ann Arbor, MI, USA. ²⁷⁸Department of Paediatrics, All India Institute of Medical Sciences, New Delhi, India. ²⁷⁹Department of Nutrition, University of the Philippines Manila, Manila, Philippines. ²⁸⁰Alliance for Improving Health Outcomes, Inc., Quezon City, Philippines. ²⁸¹Center for Integration of Data and Health Knowledge, Oswald Cruz Foundation (FIOCRUZ), Salvador, Brazil. ²⁸²Centre for Global Mental Health (CGMH), London School of Hygiene & Tropical Medicine, London, England. ²⁸³Department of Forensic Medicine, Shri Dharmasthala Manjunatheshwara University, Dharwad, India. ²⁸⁴Department of Forensic Medicine, Rajiv Gandhi University of Health Sciences, Bangalore, India. ²⁸⁵Clinical Research Development Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. ²⁸⁶Department of Maternal and Child Nursing and Public Health, Federal University of Minas Gerais, Belo Horizonte, Brazil. ²⁸⁷Institute for Social Science Research, The University of Queensland, Indooroopilly, QLD, Australia. ²⁸⁸School of Medicine, Iran University of

Medical Sciences, Tehran, Iran. ²⁸⁹School of Medicine, University of Manitoba, Winnipeg, MB, Canada. ²⁹⁰Department of Population Studies, University of Zambia, Lusaka, Zambia. ²⁹¹Campus Caucaia, Federal Institute of Education, Science and Technology of Ceará, Caucaia, Brazil. ²⁹²Neurology Department, Janakpuri Super Specialty Hospital Society, New Delhi, India. ²⁹³Department of Neurology, Govind Ballabh Institute of Medical Education and Research, New Delhi, India. ²⁹⁴Research in Nutrition and Health, National Institute of Public Health, Cuernavaca, Mexico. ²⁹⁵Department of Public Health, Wollo University, Dessie, Ethiopia. ²⁹⁶Peru Country Office, United Nations Population Fund (UNFPA), Lima, Peru. ²⁹⁷Forensic Medicine Division, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. ²⁹⁸Department of Reproductive Health and Population Studies, Bahir Dar University, Bahir Dar, Ethiopia. ²⁹⁹Department of Nursing, Arba Minch University, Arba Minch, Ethiopia. ³⁰⁰Pacific Institute for Research & Evaluation, Calverton, MD, USA. ³⁰¹Global Institute of Public Health, Ananthapuri Hospitals and Research Institute, Trivandrum, India. ³⁰²Women's Social and Health Studies Foundation, Trivandrum, India. ³⁰³Internal Medicine Programme, Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan. ³⁰⁴Department of Atherosclerosis and Coronary Heart Disease, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan. ³⁰⁵Department of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, India. ³⁰⁶Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ³⁰⁷Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ³⁰⁸Department of Forestry, Salahaddin University-Erbil, Erbil, Iraq. ³⁰⁹Department of Medicine-Huddinge, Karolinska Institute, Stockholm, Sweden. ³¹⁰Department of Epidemiology and Biostatistics, Shahrekord University of Medical Sciences, Shahrekord, Iran. ³¹¹Department of Public Health, Samara University, Semera, Ethiopia. ³¹²Health Systems and Policy Research Unit, Ahmadu Bello University, Zaria, Nigeria. ³¹³Department of Public Health Sciences, University of Miami, Miami, FL, USA. ³¹⁴Center for Health Systems Research, National Institute of Public Health, Cuernavaca, Mexico. ³¹⁵Department of Epidemiology, Arak University of Medical Sciences, Arak, Iran. ³¹⁶Computer, Electrical, and Mathematical Sciences and Engineering Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia. ³¹⁷Management and Leadership in Medical Education Research Center, Kerman University of Medical Sciences, Kerman, Iran. ³¹⁸Department of Food Science, University of Campinas (Unicamp), Campinas, Brazil. ³¹⁹School of Economics, University of Nairobi, Nairobi, Kenya. ³²⁰Department of Pediatric Medicine, The Children's Hospital & The Institute of Child Health, Multan, Pakistan. ³²¹Department of Pediatrics & Pediatric Pulmonology, Institute of Mother & Child Care, Multan, Pakistan. ³²²Department of Microbiology and Immunology, Mekelle University, Mekelle, Ethiopia. ³²³Research and Analytics Department, Initiative for Financing Health and Human Development, Chennai, India. ³²⁴Department of Research and Analytics, Bioinsilico Technologies, Chennai, India. ³²⁵Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. ³²⁶Laboratory of Public Health Indicators Analysis and Health Digitalization, Moscow Institute of Physics and Technology, Dolgoprudny, Russia. ³²⁷Experimental Surgery and Oncology Laboratory, Kursk State Medical University, Kursk, Russia. ³²⁸Suraj Eye Institute, Nagpur, India. ³²⁹Department of Clinical Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil. ³³⁰Clinical Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil. ³³¹Disease Control and Environmental Health, Makerere University, Kampala, Uganda. ³³²Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa. ³³³Department of General Surgery, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ³³⁴Department of General Surgery, Emergency Hospital of Bucharest, Bucharest, Romania. ³³⁵Department of Public Health, University of Yaoundé I, Yaoundé, Cameroon. ³³⁶Department of Biological Sciences, University of Embu, Embu, Kenya. ³³⁷Institute for Global Health Innovations, Duy Tan University, Hanoi, Vietnam. ³³⁸Faculty of Pharmacy, Duy Tan University, Da Nang, Vietnam. ³³⁹Department of Public Health, Mizan-Tepi University, Mizan Teferi, Ethiopia. ³⁴⁰Obesity Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ³⁴¹School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. ³⁴²Unit of Microbiology and Public Health, Institute of Medical Sciences, Las Tablas, Panama. ³⁴³Department of Public Health, Ministry of Health, Herrera, Panama. ³⁴⁴Administrative and Economic Sciences Department, University of Bucharest, Bucharest, Romania. ³⁴⁵Department of Obstetrics and Gynecology, University of Ibadan, Ibadan, Nigeria. ³⁴⁶Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. ³⁴⁷Department of Psychiatry, University of Lagos, Lagos, Nigeria. ³⁴⁸Centre for Healthy Start Initiative, Lagos, Nigeria. ³⁴⁹Department of Public Health, Jijiga University, Jijiga, Ethiopia. ³⁵⁰Department of Pharmacology and Therapeutics, University of Nigeria Nsukka, Enugu, Nigeria. ³⁵¹Health Systems Research Center, National Institute of Public Health, Cuernavaca, Mexico. ³⁵²Department of Project Management, National Research University Higher School of Economics, Moscow, Russia. ³⁵³Department of Medicine, University of Ibadan, Ibadan, Nigeria. ³⁵⁴Department of Medicine, University College Hospital, Ibadan, Ibadan, Nigeria. ³⁵⁵Department of Respiratory Medicine, Jagadguru Sri Shivarathreeswara Academy of Health Education and Research, Mysore, India. ³⁵⁶Department of Health Metrics, Center for Health Outcomes & Evaluation, Bucharest, Romania. ³⁵⁷Department of Research, Public Health Foundation of India, Gurugram, India. ³⁵⁸Corporate, Somnogen Canada Inc, Toronto, ON, Canada. ³⁵⁹National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia. ³⁶⁰Public Health Evidence South Asia, Manipal Academy of Higher Education, Manipal, India. ³⁶¹Division of General Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ³⁶²Department of Neurology and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ³⁶³Department of Pediatrics, RD Gardi Medical College, Ujjain, India. ³⁶⁴Global Public Health-Health Systems and Policy (HSP): Medicines Focusing Antibiotics, Karolinska Institute, Stockholm, Sweden. ³⁶⁵Research & Development Department, Kalinga Institute of Medical Sciences, Bhubaneswar, India. ³⁶⁶Department of Pediatrics, University of Melbourne, Melbourne, VIC, Australia. ³⁶⁷Population Health Theme, Murdoch Childrens Research Institute, Melbourne, VIC, Australia. ³⁶⁸Department of Midwifery, Wolaita Sodo University, Wolaita Sodo, Ethiopia. ³⁶⁹Center for Research and Innovation, Ateneo De Manila University, Pasig City, Philippines. ³⁷⁰Department of Chemistry, University of Porto, Porto, Portugal. ³⁷¹Global Development Program, Bill & Melinda Gates Foundation, Seattle, WA, USA. ³⁷²HIV and Mental Health Department, Integrated Development Foundation Nepal, Kathmandu, Nepal. ³⁷³Department of Nutrition and Food Sciences, Maragheh University of Medical Sciences, Maragheh, Iran. ³⁷⁴Dietary Supplements and Probiotic Research Center, Alborz University of Medical Sciences, Karaj, Iran. ³⁷⁵Centro de Investigaciones Clínicas, Fundación Valle del Lili, (Clinical Research Center, Valle del Lili Foundation), Cali, Colombia. ³⁷⁶Centro PROESA, Universidad ICESI, (PROESA, ICESI University), Cali, Colombia. ³⁷⁷Health Sciences Department, Muhammadiyah University of Surakarta, Sukoharjo, Indonesia. ³⁷⁸Department of Community Medicine, Datta Meghe Institute of Medical Sciences, Wardha, India. ³⁷⁹Biomedical Engineering Department, Amirkabir University of Technology, Tehran, Iran. ³⁸⁰Department of Chemistry, Sharif University of Technology, Tehran, Iran. ³⁸¹Thalassemia and Hemoglobinopathy Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. ³⁸²Metabolomics and Genomics Research Center, Tehran University of Medical Sciences, Tehran, Iran. ³⁸³Department of Natural Science, Middlesex University, London, UK. ³⁸⁴Data Mining Research Unit (DaMRA), Charles Sturt University, Wagga Wagga, NSW, Australia. ³⁸⁵Department of Community Medicine, Maharishi Markandeshwar Medical College & Hospital, Solan, India. ³⁸⁶Future Technology Research Center, National Yunlin University of Science and Technology, Yunlin, Taiwan. ³⁸⁷Institute of Research and Development, Duy Tan University, Da Nang, Vietnam. ³⁸⁸Society for Health and Demographic Surveillance, Suri, India. ³⁸⁹Department of Economics, University of Göttingen, Göttingen, Germany. ³⁹⁰Research Department, Policy Research Institute, Kathmandu, Nepal. ³⁹¹Health and Public Policy Department, Global Center for Research and Development, Kathmandu, Nepal. ³⁹²Department of Oral Pathology, Srinivas Institute of Dental Sciences, Mangalore, India. ³⁹³Department of Forensic Medicine and Toxicology, Manipal Academy of Higher Education, Mangalore, India. ³⁹⁴WHO Collaborating Centre for Public Health Education and Training, Imperial College London, London, UK. ³⁹⁵University College London Hospitals, London, UK. ³⁹⁶Department of Primary Care and Public Health, Imperial College London, London, UK. ³⁹⁷Academic Public Health England, Public Health England, London, UK. ³⁹⁸Department of Computer Science, Boston University, Boston, MA, USA. ³⁹⁹Maternal, Newborn, and Child Health Program, Bill & Melinda Gates Foundation, Seattle, WA, USA. ⁴⁰⁰Department of Mathematical Demography & Statistics, International Institute for Population Sciences, Mumbai, India. ⁴⁰¹Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Brazil. ⁴⁰²Department of Health Information Management, Manipal Academy of Higher Education, Manipal, India. ⁴⁰³Manipal Academy of Higher Education, Manipal, India.


⁴⁰⁴Epidemiology Research Unit Institute of Public Health (EPIUnit-ISPUP), University of Porto, Porto, Portugal. ⁴⁰⁵Department of Surgery, University of Minnesota, Minneapolis, MN, USA. ⁴⁰⁶Department of Surgery, University Teaching Hospital of Kigali, Kigali, Rwanda. ⁴⁰⁷Department of Clinical Research, Federal University of Uberlândia, Uberlândia, Brazil. ⁴⁰⁸Malaria Atlas Project, University of Oxford, Oxford, UK. ⁴⁰⁹Department of Health Statistics, National Institute for Medical Research, Dar es Salaam, Tanzania. ⁴¹⁰Department of Internal Medicine, University of Botswana, Gaborone, Botswana. ⁴¹¹Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India. ⁴¹²Department of Phytochemistry, Soran University, Soran, Iraq. ⁴¹³Department of Nutrition, Cihan University-Erbil, Erbil, Iraq. ⁴¹⁴Public Health and Community Medicine Department, Cairo University, Giza, Egypt. ⁴¹⁵Department of Entomology, Ain Shams University, Cairo, Egypt. ⁴¹⁶School of Public Health and Health Management, University of Belgrade, Belgrade, Serbia. ⁴¹⁷Department of Community Medicine, PSG Institute of Medical Sciences and Research, Coimbatore, India. ⁴¹⁸PSG-FAIMER South Asia Regional Institute, Coimbatore, India. ⁴¹⁹Health Economics Department, Bangladesh Institute of Development Studies (BIDS), Dhaka, Bangladesh. ⁴²⁰Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK. ⁴²¹Nuffield Department of Medicine, University of Oxford, Oxford, UK. ⁴²²Department of Geriatrics and Long Term Care, Hamad Medical Corporation, Doha, Qatar. ⁴²³Faculty of Health & Social Sciences, Bournemouth University, Bournemouth, UK. ⁴²⁴Department of Epidemiology, Indian Institute of Public Health, Gandhinagar, India. ⁴²⁵Department of Computational Biology, Indraprastha Institute of Information Technology, Delhi, India. ⁴²⁶Emergency Department, Manian Medical Centre, Erode, India. ⁴²⁷Center for Biomedical Information Technology, Shenzhen Institutes of Advanced Technology, Shenzhen, China. ⁴²⁸Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA. ⁴²⁹Department of Radiology and Interventional Neuroradiology, Isfahan University of Medical Sciences, Isfahan, Iran. ⁴³⁰Public Health Division, An-Najah National University, Nablus, Palestine. ⁴³¹Independent consultant, Karachi, Pakistan. ⁴³²Neurology Department, Ain Shams University, Cairo, Egypt. ⁴³³Department of Community Medicine, BLDE University, Vijayapur, India. ⁴³⁴Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK. ⁴³⁵Division of General Internal Medicine, Harvard University, Boston, MA, USA. ⁴³⁶Department of Community Medicine, Manipal Academy of Higher Education, Manipal, India. ⁴³⁷Institute for Population Health, King's College London, London, UK. ⁴³⁸College of Medicine, Yonsei University, Seoul, South Korea. ⁴³⁹Department of Physical Education, Federal University of Santa Catarina, Florianópolis, Brazil. ⁴⁴⁰Faculty of Medicine and Health Sciences, Shree Guru Gobind Singh Tricentenary University, Gurugram, India. ⁴⁴¹Department of Humanities and Social Sciences, Indian Institute of Technology, Roorkee, Roorkee, India. ⁴⁴²Division of Environmental Monitoring & Exposure Assessment (Water & Soil), National Institute for Research in Environmental Health, Bhopal, India. ⁴⁴³Department of Midwifery, Haramaya University, Harar, Ethiopia. ⁴⁴⁴Department No.16, Moscow Research and Practical Centre on Addictions, Moscow, Russia. ⁴⁴⁵Therapeutic Department, Balashiha Central Hospital, Balashikha, Russia. ⁴⁴⁶Nursing Care Research Center, Semnan University of Medical Sciences, Semnan, Iran. ⁴⁴⁷Department of Nursing, Muhammadiyah University of Surakarta, Surakarta, Indonesia. ⁴⁴⁸Department of Community Medicine, Ahmadu Bello University, Zaria, Nigeria. ⁴⁴⁹School of Medicine, University of California San Francisco, San Francisco, CA, USA. ⁴⁵⁰Joint Medical Program, University of California Berkeley, Berkeley, CA, USA. ⁴⁵¹Department of Biomedical Sciences, Arba Minch University, Arba Minch, Ethiopia. ⁴⁵²Non-communicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran. ⁴⁵³Department of Population Science and Human Resource Development, University of Rajshahi, Rajshahi, Bangladesh. ⁴⁵⁴Research and Development Center for Humanities and Health Management, National Institute of Health Research & Development, Jakarta, Indonesia. ⁴⁵⁵Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia. ⁴⁵⁶School of Public Health, Mekelle University, Mekelle, Ethiopia. ⁴⁵⁷Southgate Institute for Health and Society, Flinders University, Adelaide, SA, Australia. ⁴⁵⁸Department of Epidemiology and Biostatistics, University of Gondar, Gondar, Ethiopia. ⁴⁵⁹Department of Public Health and Community Medicine, Central University of Kerala, Kasaragod, India. ⁴⁶⁰Department of Endocrinology, Diabetes and Metabolism, Christian Medical College and Hospital (CMC), Vellore, India. ⁴⁶¹Institute of Public Health, Jagiellonian University Medical College, Kraków, Poland. ⁴⁶²Agency for Health Technology Assessment and Tariff System, Warsaw, Poland. ⁴⁶³Department of Pathology and Legal Medicine, University of São Paulo, Ribeirão Preto, Brazil. ⁴⁶⁴Modestum LTD, London, UK. ⁴⁶⁵Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, Netherlands. ⁴⁶⁶Department of Health Economics, Hanoi Medical University, Hanoi, Vietnam. ⁴⁶⁷Faculty of Geo-Information Science and Earth Observation, University of Twente, Enschede, Netherlands. ⁴⁶⁸Department of Allied Health Sciences, Iqra National University, Peshawar, Pakistan. ⁴⁶⁹Department of Community Medicine, Alex Ekwueme Federal University Teaching Hospital Abakaliki, Abakaliki, Nigeria. ⁴⁷⁰Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, India. ⁴⁷¹Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India. ⁴⁷²Department of Community Medicine, University of Nigeria Nsukka, Enugu, Nigeria. ⁴⁷³Insights Program, Bill & Melinda Gates Foundation, Seattle, WA, USA. ⁴⁷⁴Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ⁴⁷⁵Occupational Health Unit, Sant'Orsola Malpighi Hospital, Bologna, Italy. ⁴⁷⁶Faculty of Information Technology, Ho Chi Minh City University of Technology (HUTECH), Ho Chi Minh City, Vietnam. ⁴⁷⁷Population Dynamics and Sexual and Reproductive Health, African Population and Health Research Center, Nairobi, Kenya. ⁴⁷⁸Foundation University Medical College, Foundation University Islamabad, Islamabad, Pakistan. ⁴⁷⁹Cultures, Societies and Global Studies, & Integrated Initiative for Global Health, Northeastern University, Boston, MA, USA. ⁴⁸⁰School of Public Health, University of Nairobi, Nairobi, Kenya. ⁴⁸¹School of Health Sciences, Wuhan University, Wuhan, China. ⁴⁸²Department of Epidemiology and Biostatistics, Wuhan University, Wuhan, China. ⁴⁸³Department of Community Medicine, Rajarata University of Sri Lanka, Anuradhapura, Sri Lanka. ⁴⁸⁴Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA. ⁴⁸⁵Department of Orthopaedics, Wenzhou Medical University, Wenzhou, China. ⁴⁸⁶Global Health Research Center, Duke Kunshan University, Kunshan, China. ⁴⁸⁷Duke Global Health Institute, Duke University, Durham, NC, USA. ⁴⁸⁸Department of Diabetes and Metabolic Diseases, University of Tokyo, Tokyo, Japan. ⁴⁸⁹School of International Development and Global Studies, University of Ottawa, Ottawa, ON, Canada. ⁴⁹⁰The George Institute for Global Health, University of Oxford, Oxford, UK. ⁴⁹¹Department of Midwifery, Wolkite University, Wolkite, Ethiopia. ⁴⁹²Department of Public Health, Wollega University, Nekemte, Ethiopia. ⁴⁹³Centre for Suicide Research and Prevention, University of Hong Kong, Hong Kong, China. ⁴⁹⁴Department of Social Work and Social Administration, University of Hong Kong, Hong Kong, China. ⁴⁹⁵Department of Neuropsychopharmacology, National Center of Neurology and Psychiatry, Kodaira, Japan. ⁴⁹⁶Department of Public Health, Juntendo University, Tokyo, Japan. ⁴⁹⁷Department of Health Policy and Management, Jackson State University, Jackson, MS, USA. ⁴⁹⁸School of Medicine, Tsinghua University, Beijing, China. ⁴⁹⁹School of Public Health and Management, Hubei University of Medicine, Shiyan, China. ⁵⁰⁰Cancer Institute, Hacettepe University, Ankara, Turkey. ⁵⁰¹Department of Obstetrics and Gynaecology, Fazaia Medical College, Islamabad, Pakistan. ⁵⁰²Department of Obstetrics and Gynaecology, Air University, Islamabad, Pakistan. ⁵⁰³Department of Pharmaceutics, Dow University of Health Sciences, Karachi, Pakistan. ⁵⁰⁴Department of Parasitology and Entomology, Tarbiat Modares University, Tehran, Iran. ⁵⁰⁵Institute for Immunological Research, University of Cartagena, Cartagena, Colombia. ⁵⁰⁶Department of Paediatrics & Child Health, University of Cape Town, Cape Town, South Africa. ⁵⁰⁷Unit on Child & Adolescent Health, Medical Research Council South Africa, Cape Town, South Africa. ⁵⁰⁸Laboratory of Genetics and Genomics, Moscow Research and Practical Centre on Addictions, Moscow, Russia. ⁵⁰⁹Addictology Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. ⁵¹⁰Pediatrics Department, Russian Medical Academy of Continuous Professional Education, Moscow, Russia. ⁵¹¹Department of Pediatrics and Child Health Nursing, Bahir Dar University, Bahir Dar, Ethiopia. ⁵¹²School of Public Health, Wuhan University of Science and Technology, Wuhan, China. ⁵¹³Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan, China. ⁵¹⁴School of Medicine, Wuhan University, Wuhan, China. ⁵¹⁵School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, China. ⁵¹⁶Indian Institute of Public Health, Public Health Foundation of India, Gurugram, India. ⁵¹⁷Health Technology Assessment Unit, Department of Health Philippines, Manila, Philippines. ⁵¹⁸#MentalHealthPH, Inc., Quezon City, Philippines.



Extended Data Fig. 1 | Analytic process overview. The process used to produce EBF prevalence estimates across LMICs involved three main parts. In the data-processing steps (orange), data were identified, extracted, and prepared for use in the models. In the modelling phase (yellow), we used these data and covariates in stacked generalization ensemble models and spatiotemporal Gaussian process models for each EBF indicator. In post-processing (green), we calibrated the prevalence estimates to match the GBD 2019¹² study estimates and aggregated the estimates to the first- and second-administrative levels in each country.



Extended Data Fig. 2 | National time series plots and aggregated input data. National time series plots of the post-GBD calibration final estimates by country during 2000–2018. Uncertainty ranges are presented in grey, and aggregated input data are classified by survey series (purple for country-specific, green for DHS, and yellow for MICS surveys), data type (square for polygon, circle for point data), and whether the survey is nationally or subnationally representative).



Extended Data Fig. 3 | Relative uncertainty in EBF estimates for 2018. Relative uncertainty in second-administrative-level estimates compared with mean estimated EBF prevalence in each second-administrative-level unit for 2018. Mean prevalence and relative uncertainty are split into population-weighted quartiles. These cut-off points for relative uncertainty (calculated as the absolute range of the uncertainty intervals divided by the estimate) are 0.684 (25th percentile), 0.916 (50th percentile), and 1.271 (75th percentile), respectively. The cut-off points for EBF prevalence are 25.8% (25th percentile), 35.4% (50th percentile), and 49.4% (75th percentile), respectively. Units in which our estimates are more uncertain are coloured with a scale of increasing blue hue, whereas areas in which the mean estimates of EBF are low are coloured with a scale of increasing red hue. Purple areas have low, but uncertain, estimates of EBF. White areas have high EBF estimates that are fairly certain. Relative uncertainty is defined as the ratio of the width of the 95% uncertainty interval to mean estimate. Maps reflect administrative boundaries, land cover, lakes, and population; grey-coloured grid cells had fewer than ten people per 1×1 -km grid cell and were classified as ‘barren or sparsely vegetated’, or were not included in this analysis^{50–55}.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection No primary data collection was carried out for these analyses.

Data analysis These analyses were carried out using R version 3.5.0. The main geostatistical models were fit using R-INLA version 18.07.12. All code used for these analyses is publicly available online before publication.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The findings of this study are supported by data that are available in public online repositories, data that are publicly available on request from the data provider, and data that are not publicly available due to restrictions by the data provider and which were used under license for the current study. Details on data sources can be found on the GHDx website (upon publication: http://ghdx.healthdata.org/lbd-publication-data-input-sources?field_rec_ihme_publication_tid=29093), including information about the data provider and links to where the data can be accessed or requested (where available). We have also provided maps of the data included in our models in Supplementary Figures 1–5. Outputs of these EBF analyses can be explored at various spatial levels (national, administrative, and 5 × 5-km levels) through our customized visualisation tool (<https://vizhub.healthdata.org/lbd/ebf>).

Administrative boundaries were retrieved from the Database of Global Administrative Areas (GADM)[50]. Land cover was retrieved from the online Data Pool,

courtesy of the NASA EOSDIS Land Processes Distributed Active Archive Center, USGS/Earth Resources Observation and Science Center, Sioux Falls, South Dakota [51]. Lakes were retrieved from the Global Lakes and Wetlands Database, courtesy of the World Wildlife Fund and the Center for Environmental Systems Research, University of Kassel [52]. Populations were retrieved from WorldPop [53].

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size was calculated as the number of unique data source-location pairs with survey responses regarding the feeding of children less than 6 months old at the time of the survey, in order to estimate exclusive breastfeeding (EBF) prevalence. This sample size is reported in the methods section: "This dataset represents 302,435 infants aged 0–5 months (infants up to the age of 6 months) across 94 LMICs, and was geocoded to 69,179 coordinates corresponding to cluster-level boundaries and 67,750 subnational polygon boundaries. Across the 94 countries in the analysis, there were 1,727 first-administrative-level boundaries (e.g., provinces) and 24,556 second-administrative-level boundaries (e.g., districts)." This is an observational study with no hypothesis testing and the sample size was not pre-specified. We evaluate the overall performance of our modelling strategy, given the available data, as part of a validation exercise as described in the 'Model validation' section of the methods, and as reported in the Supplementary Information (Supplementary Section 4.3).
Data exclusions	Surveys or reports that did not contain the relevant variable (i.e., survey responses regarding the feeding practices of children less than 6 months old at the time of the survey) or did not contain subnational geographic detail or could otherwise not be geolocated, or were outside the geographic (i.e., LMICs) or temporal (i.e., 1998-2018) scope of the study, were excluded as not relevant for these analyses. Surveys with microdata (i.e., individual-level responses) were excluded if they did not contain questions about the age of the child, whether the child is still being breastfed, and whether the child has consumed other food or liquid items. Survey reports without microdata were excluded if the survey did not contain a prevalence number for EBF with a sample size or the lower and upper bounds for the 95% confidence interval. Additionally, we excluded surveys that only asked mothers and caregivers if infants had been exclusively breastfed (e.g., "did you exclusively breastfeed?") without ascertaining further information. This exclusion criterion was established after finding, by comparing responses in surveys containing both types of questions, that many mothers and caregivers stated infants had exclusively breastfed but also answered that they had received food or water in the 24-hour recall questions. This may be due to the respondent misunderstanding the meaning of "exclusive breastfeeding" or the question may have been misinterpreted with translation. Instead, we classified children as exclusively breastfed if survey responses indicated they received only breast-milk and medicines (i.e., oral rehydration salts, vitamins, or other medicines) without other foods or liquids on the 24-hour period prior to the survey.
Replication	This is an observational study using many years of survey and report data and in principle could be replicated. Due to the time required to extract, process, and geo-locate all data, as well as to run the statistical models, we have not undertaken an explicit replication analysis.
Randomization	Randomization was not relevant to this study. This analysis is an observational mapping study and there were no experimental groups.
Blinding	Blinding was not relevant to this study, as it was an observational study using survey and report data.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging